BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3] [Cited by in Crossref: 636] [Cited by in F6Publishing: 661] [Article Influence: 45.4] [Reference Citation Analysis]
Number Citing Articles
1 Hu TH, Chen CL, Lin CC, Wang CC, Chiu KW, Yong CC, Liu YW, Eng HL. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation. Transplantation. 2014;97 Suppl 8:S53-S59. [PMID: 24849836 DOI: 10.1097/01.tp.0000446278.43804.f9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
2 Lin C, Lin C, Mo L, Chang C, Perng D, Hsu C, Lo G, Chen Y, Yen Y, Hu J, Yu M, Lee P, Lin J, Yang S. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. Journal of Hepatology 2013;58:730-5. [DOI: 10.1016/j.jhep.2012.11.045] [Cited by in Crossref: 86] [Cited by in F6Publishing: 69] [Article Influence: 9.6] [Reference Citation Analysis]
3 Peng C, Lai H, Li Y, Su W, Chuang P, Kao J. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther 2012;35:458-68. [DOI: 10.1111/j.1365-2036.2011.04973.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
4 Lau GK, Wang FS. Management of chronic hepatitis B e antigen-negative disease: another step forward. J Infect Dis 2012;205:7-9. [PMID: 22095767 DOI: 10.1093/infdis/jir694] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Gish R, Jia JD, Locarnini S, Zoulim F. Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis. 2012;12:341-353. [PMID: 22326017 DOI: 10.1016/s1473-3099(11)70314-0] [Cited by in Crossref: 98] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
6 Wang Y, Zheng S, Zhang Y, Qin J, Lin H, Liu X, Shen C, Jiang M. Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa. Scandinavian Journal of Gastroenterology 2012;48:213-7. [DOI: 10.3109/00365521.2012.749513] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
7 Phillips S, Chokshi S, Chatterji U, Riva A, Bobardt M, Williams R, Gallay P, Naoumov NV. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production. Gastroenterology 2015; 148: 403-14. e7. [PMID: 25305505 DOI: 10.1053/j.gastro.2014.10.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
8 Liu J, Yang HI, Lee MH, Batrla-Utermann R, Jen CL, Lu SN, Wang LY, You SL, Hsiao CK, Chen CJ; REVEAL-HBV Study Group. Distinct seromarkers predict different milestones of chronic hepatitis B progression. Hepatology. 2014;60:77-86. [PMID: 24700432 DOI: 10.1002/hep.27083] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
9 Specialist Panel on Chronic Hepatitis B in the Middle East. A review of chronic hepatitis B epidemiology and management issues in selected countries in the Middle East. J Viral Hepat. 2012;19:9-22. [PMID: 22187943 DOI: 10.1111/j.1365-2893.2011.01511.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
10 Karagoz E, Ulcay A, Tanoglu A, Kara M, Turhan V, Erdem H, Oncul O, Gorenek L. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients. Eur J Gastroenterol Hepatol. 2014;26:1320-1324. [PMID: 25210777 DOI: 10.1097/meg.0000000000000203] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
11 Kuo L, Lee C, Hung C, Wang J, Hu T, Lu S, Changchien C, Chen C. High Risk of Hepatitis B Virus Reactivation in Nucleos(t)ide Analogue-Induced Hepatitis B e Antigen Seroconverters Older Than 40 Years. Dig Dis Sci 2014;59:2580-7. [DOI: 10.1007/s10620-014-3194-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
12 Chan HL. Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong. Journal of Hepatology 2009;51:1088-90. [DOI: 10.1016/j.jhep.2009.09.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
13 Seth AK. HBsAg Quantification in Clinical Practice. J Clin Exp Hepatol 2012;2:75-80. [PMID: 25755408 DOI: 10.1016/S0973-6883(12)60084-X] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
14 Jiang L, Wu X, He F, Liu Y, Hu X, Takeda S, Qing Y. Genetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog. PLoS One 2016;11:e0147440. [PMID: 26800464 DOI: 10.1371/journal.pone.0147440] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Gong X, Yang J, Tang J, Gu C, Huang L, Zheng Y, Liang H, Wang M, Wu C, Chen Y. A Mechanistic Assessment of the Discordance between Normal Serum Alanine Aminotransferase Levels and Altered Liver Histology in Chronic Hepatitis B. PLoS One. 2015;10:e0134532. [PMID: 26230094 DOI: 10.1371/journal.pone.0134532] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
16 Liu F, Wang L, Li XY, Liu YD, Wang JB, Zhang ZH, Wang YZ. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol. 2011;26:456-460. [PMID: 21332542 DOI: 10.1111/j.1440-1746.2010.06492.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 6.0] [Reference Citation Analysis]
17 Lv GC, Yao JM, Yang YD, Zheng L, Sheng JF, Chen Y, Li LJ. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(22): 3481-3486 [PMID: 23801842 DOI: 10.3748/wjg.v19.i22.3481] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
18 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother 2013;57:6325-32. [PMID: 24100506 DOI: 10.1128/AAC.01742-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
19 Al-Ashgar HI, Khan MQ, Aljumah A, Sanai FM, Abdo AA, Dafalla MM, Fagih MA, Bzeizi KI. Efficacy of peginterferon α-2a and predictors of response in HBeAg-negative, genotype D-naive patients. Hepatol Int 2012;6:718-26. [PMID: 23936583 DOI: 10.1007/s12072-011-9319-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
20 Lesmana CRA, Gani RA, Hasan I, Simadibrata M, Sulaiman AS, Pakasi LS, Budihusodo U, Krisnuhoni E, Lesmana LA. Significant hepatic histopathology in chronic hepatitis B patients with serum ALT less than twice ULN and high HBV-DNA levels in Indonesia: Hepatic histopathology in normal ALT. Journal of Digestive Diseases 2011;12:476-80. [DOI: 10.1111/j.1751-2980.2011.00540.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
21 Pei SN, Chen CH. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. Leuk Lymphoma 2015;56:1611-8. [PMID: 25248874 DOI: 10.3109/10428194.2014.964699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhao ZG, Han T, Gao YT, Gao YY, Zhang Y, Wu ZP. Causes and clinical outcomes of acute-on-chronic liver failure in patients with hepatitis B virus infection: an analysis of 289 cases. Shijie Huaren Xiaohua Zazhi 2009; 17(31): 3269-3272 [DOI: 10.11569/wcjd.v17.i31.3269] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Lu JJ, Liu K, Ma YJ, Wang J, Chen EQ, Tang H. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil. J Viral Hepat. 2013;20 Suppl 1:40-45. [PMID: 23458523 DOI: 10.1111/jvh.12062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
24 Fung J, Wong DK, Seto WK, Kopaniszen M, Lai CL, Yuen MF. Hepatitis B surface antigen seroclearance: Relationship to hepatitis B e-antigen seroclearance and hepatitis B e-antigen-negative hepatitis. Am J Gastroenterol. 2014;109:1764-1770. [PMID: 25244963 DOI: 10.1038/ajg.2014.301] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
25 Fuentes Olmo J, Uribarrena Amézaga R. [Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?]. Gastroenterol Hepatol 2011;34:492-503. [PMID: 21550145 DOI: 10.1016/j.gastrohep.2011.02.009] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Sun WC, Tang PL, Chen WC, Tsay FW, Wang HM, Tsai TJ, Kao SS, Cheng JS, Tsai WL. Hepatitis B Virus Screening Before Cancer Chemotherapy in Taiwan: A Nationwide Population-Based Study. Front Med (Lausanne) 2021;8:657109. [PMID: 34336877 DOI: 10.3389/fmed.2021.657109] [Reference Citation Analysis]
27 Viganò M, Mangia G, Lampertico P. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? Liver Int 2014;34 Suppl 1:120-6. [PMID: 24373088 DOI: 10.1111/liv.12401] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
28 Han GR, Jiang HX, Yue X, Ding Y, Wang CM, Wang GJ, Yang YF. Efficacy and safety of telbivudine treatment: an open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2015;22:754-762. [PMID: 25641421 DOI: 10.1111/jvh.12379] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
29 Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Hai-Jun Huang. Comparison of histologic characteristics of Chinese chronic hepatitis B patients with persistently normal or mildly elevated ALT. PLoS One. 2013;8:e80585. [PMID: 24260428 DOI: 10.1371/journal.pone.0080585] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
30 You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. World J Gastroenterol 2014; 20(37): 13293-13305 [PMID: 25309066 DOI: 10.3748/wjg.v20.i37.13293] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
31 Lee SL, Chin TY, Lai CL, Wang WH. Sedum mexicanum Britt. Induces Apoptosis of Primary Rat Activated Hepatic Stellate Cells. Evid Based Complement Alternat Med 2015;2015:194373. [PMID: 26078767 DOI: 10.1155/2015/194373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
32 Ozoya OO, Sokol L, Dalia S. Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies. J Clin Transl Hepatol 2016;4:143-50. [PMID: 27350944 DOI: 10.14218/JCTH.2016.00005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
33 Liu C, Chen P, Chen D, Kao J. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013;7:316-26. [DOI: 10.1007/s12072-011-9279-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
34 Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol. 2012;36:84-93. [PMID: 21920838 DOI: 10.1016/j.clinre.2011.07.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
35 Striki A, Manolakopoulos S, Deutsch M, Kourikou A, Kontos G, Kranidioti H, Hadziyannis E, Papatheodoridis G. Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B. Liver Int. 2017;37:1642-1650. [PMID: 28345181 DOI: 10.1111/liv.13432] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
36 Almasio PL, Babudieri S, Barbarini G, Brunetto M, Conte D, Dentico P, Gaeta GB, Leonardi C, Levrero M, Mazzotta F, Morrone A, Nosotti L, Prati D, Rapicetta M, Sagnelli E, Scotto G, Starnini G. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Digestive and Liver Disease 2011;43:589-95. [DOI: 10.1016/j.dld.2010.12.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
37 Begini P, Cox MC, Angeletti S, Gigante E, Baccini F, Fonzo MD, Fave GD, Marignani M. Effectiveness of entecavir in the management of acute hepatitis B developing in a patient with Hodgkin's lymphoma: A case report. Scandinavian Journal of Infectious Diseases 2011;43:750-2. [DOI: 10.3109/00365548.2011.574149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Jang JW, Choi JY, Kim YS, Woo HY, Choi SK, Lee CH, Kim TY, Sohn JH, Tak WY, Han KH. Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 2015;61:1809-20. [PMID: 25627342 DOI: 10.1002/hep.27723] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 12.3] [Reference Citation Analysis]
39 Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, Narkewicz MR, Rosenthal P, Schwarz KB, McMahon BJ. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. Hepatology. 2010;52:2192-2205. [PMID: 20890947 DOI: 10.1002/hep.23934] [Cited by in Crossref: 101] [Cited by in F6Publishing: 84] [Article Influence: 8.4] [Reference Citation Analysis]
40 Kim BK, Kim do Y, Han KH, Park JY, Kim JK, Paik YH, Lee KS, Chon CY, Ahn SH. Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. Am J Gastroenterol. 2011;106:1654-1652, 1730. [PMID: 21691339 DOI: 10.1038/ajg.2011.160] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
41 Jung YK, Yeon JE, Lee KG, Jung ES, Kim JH, Kim JH, Seo YS, Yim HJ, Um SH, Ryu HS. Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol. 2011;17:261-267. [PMID: 22310790 DOI: 10.3350/kjhep.2011.17.4.261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
42 Kwon JH, Kim YS, Kim SG, Jang JW, Kim TH, Jung YK, Kwon OS. The Efficacy and Safety of Peginterferon-α-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting. Gut Liver. 2013;7:197-205. [PMID: 23560156 DOI: 10.5009/gnl.2013.7.2.197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
43 Shan C, Yin GQ, Wu P. Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report. J Med Case Rep. 2014;8:281. [PMID: 25146249 DOI: 10.1186/1752-1947-8-281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
44 Keating GM. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs. 2011;71:2511-2529. [PMID: 22141390 DOI: 10.2165/11208510-000000000-00000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
45 Wang Y, Zhao C, Zhang L, Yu W, Shen C, Wang W, Zhen Z, Zhou J. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients. Antiviral Res. 2014;103:51-59. [PMID: 24418572 DOI: 10.1016/j.antiviral.2014.01.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
46 Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol 2009;51:403-10. [PMID: 19467727 DOI: 10.1016/j.jhep.2009.04.003] [Cited by in Crossref: 83] [Cited by in F6Publishing: 82] [Article Influence: 6.4] [Reference Citation Analysis]
47 Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV;  GLOBE Study Group. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486-495. [PMID: 19027013 DOI: 10.1053/j.gastro.2008.10.026] [Cited by in Crossref: 412] [Cited by in F6Publishing: 394] [Article Influence: 29.4] [Reference Citation Analysis]
48 Scott LJ, Keating GM. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2009;69:1003-1033. [PMID: 19496629 DOI: 10.2165/00003495-200969080-00005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
49 Montagnani M, Giandinoto M, Lisotti A, Galli S, Azzaroli F, Buonfiglioli F, Turco L, Aldini R, Mazzella G. High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. Dig Dis Sci 2012;57:561-7. [PMID: 21881973 DOI: 10.1007/s10620-011-1873-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140-1149.e3; quiz e13-14. [PMID: 22333950 DOI: 10.1053/j.gastro.2012.02.007] [Cited by in Crossref: 307] [Cited by in F6Publishing: 295] [Article Influence: 30.7] [Reference Citation Analysis]
51 Sohn W, Paik YH, Cho JY, Ahn JM, Choi GS, Kim JM, Kwon CH, Joh JW, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load. J Viral Hepat 2015;22:539-50. [PMID: 25377516 DOI: 10.1111/jvh.12356] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
52 Dong H, Ni L, Sheng G, Song H, Xu J, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis. Journal of Clinical Virology 2013;57:209-14. [DOI: 10.1016/j.jcv.2013.03.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 8.0] [Reference Citation Analysis]
53 Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X, Shen CH, Luo Y, Xin TY, Wang SY. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis. 2009;10:321-327. [PMID: 19906113 DOI: 10.1111/j.1751-2980.2009.00403.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
54 Chen GY, Zhu MF, Zheng DL, Bao YT, Wang J, Zhou X, Lou GQ. Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol 2014; 20(25): 8195-8200 [PMID: 25009392 DOI: 10.3748/wjg.v20.i25.8195] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
55 Sun Z, Liu X, Jiang J, Huang H, Wang J, Wu D, Li L. Toward Biomarker Development in Large Clinical Cohorts: An Integrated High-Throughput 96-Well-Plate-Based Sample Preparation Workflow for Versatile Downstream Proteomic Analyses. Anal Chem 2016;88:8518-25. [PMID: 27471874 DOI: 10.1021/acs.analchem.6b01333] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
56 Xie ZB, Wang XB, Fu DL, Zhong JH, Yang XW, Li LQ. Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies/mL. Onco Targets Ther 2016;9:4593-603. [PMID: 27524913 DOI: 10.2147/OTT.S104300] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
57 Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010;17:16-22. [PMID: 19622117 DOI: 10.1111/j.1365-2893.2009.01146.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 7.1] [Reference Citation Analysis]
58 Lui GCY, Wong NS, Wong RYK, Tse YK, Wong VWS, Leung CC, Chan HLY, Wong GLH. Antiviral Therapy for Hepatitis B Prevents Liver Injury in Patients With Tuberculosis and Hepatitis B Coinfection. Clin Infect Dis 2020;70:660-6. [PMID: 30919884 DOI: 10.1093/cid/ciz241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
59 Yang H, Hung H, Lee M, Liu J, Jen C, Su J, Wang L, Lu S, You S, Iloeje UH, Chen C. Incidence and Determinants of Spontaneous Seroclearance of Hepatitis B e Antigen and DNA in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 2012;10:527-534.e2. [DOI: 10.1016/j.cgh.2011.12.019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
60 Jang JW, Kim YW, Lee SW, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK, Chung KW. Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma. PLoS One. 2015;10:e0122041. [PMID: 25894607 DOI: 10.1371/journal.pone.0122041] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
61 Zhang L, Li H, Ren H, Hu P. Circulating PD-1hiCXCR5+CD4+ T cells are associated with a decrease in hepatitis B surface antigen levels in patients with chronic hepatitis B who are receiving peginterferon-α therapy. Molecular Immunology 2018;103:270-8. [DOI: 10.1016/j.molimm.2018.10.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Hsu CS, Lang HC, Huang KY, Lin HH, Chen CL. Association of Rheumatoid Arthritis and Hepatitis B Infection: A Nationwide Nested Case-Control Study From 1999 to 2009 in Taiwan. Medicine (Baltimore) 2016;95:e3551. [PMID: 27149469 DOI: 10.1097/MD.0000000000003551] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
63 Qiu Q, Li Y, Duan XW, Yang LK, Chen Y, Li H, Wang L, Duan ZP. Impact of a new reimbursement program on hepatitis B antiviral medication cost and utilization in Beijing, China. PLoS One 2014;9:e109652. [PMID: 25329072 DOI: 10.1371/journal.pone.0109652] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
64 Gao FY, Liu Y, Li XS, Ye XQ, Sun L, Geng MF, Wang R, Liu HM, Zhou XB, Gu LL, Liu YM, Wan G, Wang XB. Score model for predicting acute-on-chronic liver failure risk in chronic hepatitis B. World J Gastroenterol 2015; 21(27): 8373-8381 [PMID: 26217089 DOI: 10.3748/wjg.v21.i27.8373] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
65 Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. J Gastroenterol Hepatol. 2009;24:1179-1186. [PMID: 19682192 DOI: 10.1111/j.1440-1746.2009.05924.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
66 Cross V, Larkins S. Management of chronic Hepatitis B infection in the remote primary health care setting: The search for a suitable guideline: MANAGING HEPATITIS B IN REMOTE SETTINGS. Australian Journal of Rural Health 2011;19:95-100. [DOI: 10.1111/j.1440-1584.2011.01190.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
67 Cooksley WG. Do we need to determine viral genotype in treating chronic hepatitis B? J Viral Hepat. 2010;17:601-610. [PMID: 20529201 DOI: 10.1111/j.1365-2893.2010.01326.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
68 Lui YY, Chan HL. Treatment of chronic hepatitis B: focus on telbivudine. Expert Review of Anti-infective Therapy 2014;7:259-68. [DOI: 10.1586/eri.09.6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
69 Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, Tan DM, Chen XY, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Wat C, Bernaards C, Cui Y, Marcellin P. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011;54:1591-1599. [PMID: 22045673 DOI: 10.1002/hep.24555] [Cited by in Crossref: 145] [Cited by in F6Publishing: 132] [Article Influence: 14.5] [Reference Citation Analysis]
70 Cheong HS, Lee JH, Yu SJ, Yoon JH, Lee HS, Cheong JY, Cho SW, Park NH, Park BL, Namgoong S, Kim LH, Shin HD, Kim YJ. Association of VARS2-SFTA2 polymorphisms with the risk of chronic hepatitis B in a Korean population. Liver Int 2015;35:1934-40. [PMID: 25404243 DOI: 10.1111/liv.12740] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
71 Lee YB, Lee J, Kim YJ, Yoon J, Lee H. The effect of therapeutic vaccination for the treatment of chronic hepatitis B virus infection: Therapeutic Vaccination in Chronic Hepatitis B. J Med Virol 2015;87:575-82. [DOI: 10.1002/jmv.24091] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
72 Wu CY, Hsiao LT, Chiou TJ, Gau JP, Liu JH, Yu YB, Wu YT, Liu CJ, Huang YC, Hung MH, Chen PM, Huang YH, Tzeng CH. Lymphocyte/monocyte ratio and cycles of rituximab-containing therapy are risk factors for hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma and resolved hepatitis B. Leuk Lymphoma 2015;56:2357-64. [PMID: 25459444 DOI: 10.3109/10428194.2014.991922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
73 He Q, He Q, Qin X, Li S, Li T, Xie L, Deng Y, He Y, Chen Y, Wei Z. The Relationship between Inflammatory Marker Levels and Hepatitis C Virus Severity. Gastroenterol Res Pract 2016;2016:2978479. [PMID: 28090206 DOI: 10.1155/2016/2978479] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
74 Cheng HY, Kang PJ, Chuang YH, Wang YH, Jan MC, Wu CF, Lin CL, Liu CJ, Liaw YF, Lin SM, Chen PJ, Lee SD, Yu MW. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. PLoS One. 2014;9:e95870. [PMID: 25427199 DOI: 10.1371/journal.pone.0095870] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
75 Chen C, Chang M. HEPATITIS B AND PREGNANCY, THE SCIENTIFIC BASIS FOR PERINATAL PREVENTION. Fet Matern Med Rev 2010;21:89-113. [DOI: 10.1017/s0965539510000021] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
76 Duarte-rojo A, Feld JJ. Hepatitis B Biomarkers: Clinical Significance of the Old and the New. Curr Hepatitis Rep 2010;9:187-96. [DOI: 10.1007/s11901-010-0053-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
77 Desalegn H, Aberra H, Berhe N, Gundersen SG, Johannessen A. Are non-invasive fibrosis markers for chronic hepatitis B reliable in sub-Saharan Africa? Liver Int 2017;37:1461-7. [PMID: 28222249 DOI: 10.1111/liv.13393] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
78 Liu JY, Sheng YJ, Ding XC, Tang H, Tong SW, Zhang DZ, Zhou Z, Hu P, Liao Y, Ren H. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis. J Formos Med Assoc. 2015;114:164-173. [PMID: 25678179 DOI: 10.1016/j.jfma.2012.10.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
79 Ahn SH, Kweon YO, Paik SW, Sohn JH, Lee KS, Kim DJ, Piratvisuth T, Yuen MF, Chutaputti A, Chao YC. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatol Int. 2011;Oct 12; Epub ahead of print. [PMID: 21989925 DOI: 10.1007/s12072-011-9314-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
80 Liaw Y. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: A review. Hepatology 2011;54:E1-9. [DOI: 10.1002/hep.24473] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.7] [Reference Citation Analysis]
81 Chotiyaputta W, Lok ASF. Endpoints of hepatitis B treatment: Endpoints of HBV treatment. Journal of Viral Hepatitis 2010;17:675-84. [DOI: 10.1111/j.1365-2893.2010.01369.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
82 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Cheng Y, Guindon S, Rodrigo A, Lim SG. Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy. J Hepatol. 2013;58:217-224. [PMID: 23023011 DOI: 10.1016/j.jhep.2012.09.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
84 Yang J, Chen J, Ye P, Jin L, Wu W, Sheng G, Li LJ. HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients. J Transl Med 2014;12:183. [PMID: 24962263 DOI: 10.1186/1479-5876-12-183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
85 Hsu CW, Yeh CT. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy. Hepatology. 2011;54:101-108. [PMID: 21503942 DOI: 10.1002/hep.24363] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
86 Chan HL. Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: is it too late? Dig Dis Sci 2010;55:2126-8. [PMID: 20458619 DOI: 10.1007/s10620-010-1266-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
87 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother. 2013;57:6325-6332. [PMID: 24100506 DOI: 10.1128/aac.01742-13aac.01742-13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Lin LY, Wong VW, Zhou HJ, Chan HY, Gui HL, Guo SM, Wang H, Huang L, Bao SS, Xie Q. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. J Med Virol. 2010;82:1494-1500. [PMID: 20648602 DOI: 10.1002/jmv.21863] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
89 Mota LMHD, Cruz BA, Brenol CV, Pollak DF, Pinheiro GDRC, Laurindo IMM, Pereira IA, Carvalho JFD, Bertolo MB, Pinheiro MDM, Freitas MVC, Silva NAD, Louzada‐júnior P, Sampaio‐barros PD, Giorgi RDN, Lima RAC, Andrade LEC. Segurança do uso de terapias biológicas para o tratamento de artrite reumatoide e espondiloartrites. Revista Brasileira de Reumatologia 2015;55:281-309. [DOI: 10.1016/j.rbr.2014.06.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
90 Azmi AN, Tan SS, Mohamed R. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol 2014; 20(34): 12045-12055 [PMID: 25232242 DOI: 10.3748/wjg.v20.i34.12045] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
91 Buster EH, Schalm SW, Janssen HL. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol. 2008;22:1093-1108. [PMID: 19187869 DOI: 10.1016/j.bpg.2008.11.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
92 Chiang LT, Yao M, Ko BS, Chen CH. Development of immunity against hepatitis B virus after donor lymphocyte infusion in a peripheral blood stem cell transplantation recipient with chronic hepatitis B. Infection 2011;39:363-5. [PMID: 21544586 DOI: 10.1007/s15010-011-0120-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
93 Chao DC, Hu KQ. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther. 2013;7:777-788. [PMID: 23990707 DOI: 10.2147/dddt.s33947] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
94 Liaw YF. Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros. Dig Liver Dis 2010;42 Suppl 3:S293-7. [PMID: 20547317 DOI: 10.1016/S1590-8658(10)60519-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
95 Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, Wang GJ, Tang X, Fang ZX. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011;55:1215-1221. [PMID: 21703206 DOI: 10.1016/j.jhep.2011.02.032] [Cited by in Crossref: 256] [Cited by in F6Publishing: 222] [Article Influence: 23.3] [Reference Citation Analysis]
96 He J, Zhou D, Tong G, Xing Y, Chen Y, Zhang X, Zhan B, Gao H, Zhou X, Xiong Y, Liu X, Peng L, Qiu M, Zheng Y. Efficacy and safety of a chinese herbal formula (invigorating kidney and strengthening spleen) in chronic hepatitis B virus carrier: results from a multicenter, randomized, double-blind, and placebo-controlled trial. Evid Based Complement Alternat Med. 2013;2013:961926. [PMID: 23935692 DOI: 10.1155/2013/961926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
97 Lai M, Liaw Y. Chronic Hepatitis B: Past, Present, and Future. Clinics in Liver Disease 2010;14:531-46. [DOI: 10.1016/j.cld.2010.05.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
98 Cai SH, Lv FF, Zhang YH, Jiang YG, Peng J. Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB. BMC Infect Dis. 2014;14:85. [PMID: 24528480 DOI: 10.1186/1471-2334-14-85] [Cited by in Crossref: 28] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
99 Wang J. Clinical utility of entecavir for chronic hepatitis B in Chinese patients. Drug Des Devel Ther. 2013;8:13-24. [PMID: 24376343 DOI: 10.2147/dddt.s41423] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
100 Lo GH. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with cirrhosis: facts or fiction? Hepatology 2014;60:1797. [PMID: 24519364 DOI: 10.1002/hep.27073] [Reference Citation Analysis]
101 Wang M, Gong Q, Zhang J, Chen L, Zhang Z, Lu L, Yu D, Han Y, Zhang D, Chen P, Zhang X, Yuan Z, Huang J, Zhang X. Characterization of gene expression profiles in HBV-related liver fibrosis patients and identification of ITGBL1 as a key regulator of fibrogenesis. Sci Rep 2017;7:43446. [PMID: 28262670 DOI: 10.1038/srep43446] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
102 Devi U, Locarnini S. Hepatitis B antivirals and resistance. Current Opinion in Virology 2013;3:495-500. [DOI: 10.1016/j.coviro.2013.08.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
103 Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P; Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20. [PMID: 21378402 DOI: 10.1136/ard.2010.144998] [Cited by in Crossref: 262] [Cited by in F6Publishing: 212] [Article Influence: 23.8] [Reference Citation Analysis]
104 Luo A, Jiang X, Ren H. Entecavir-based combination therapies for chronic hepatitis B: A meta-analysis. Medicine (Baltimore) 2018;97:e13596. [PMID: 30572464 DOI: 10.1097/MD.0000000000013596] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Lau GK, Leung N. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. Korean J Hepatol. 2010;16:315-320. [PMID: 20924215 DOI: 10.3350/kjhep.2010.16.3.315] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
106 Lau GKK. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon. Liver International 2009;29:125-9. [DOI: 10.1111/j.1478-3231.2008.01946.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
107 Zhong JH, Ke Y, Zhu SL, Wang L, Luo CP, Gong WF, You XM, Ma L, Xiang BD, Li LQ. Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection. Onco Targets Ther 2016;9:6897-907. [PMID: 27877054 DOI: 10.2147/OTT.S120062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
108 Ceccarelli L, Salpini R, Sarmati L, Svicher V, Bertoli A, Sordillo P, Ricciardi A, Perno CF, Andreoni M, Sarrecchia C. Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy. J Infect. 2012;65:180-183. [PMID: 22138369 DOI: 10.1016/j.jinf.2011.11.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
109 Visvanathan K, Lang T, Ryan K, Wilson R, Skinner NA, Thompson AJ, Ahn SH, Weilert F, Abbott W, Gane E, Colledge D, Li K, Locarnini S, Mansell A, Revill PA. Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients. J Viral Hepat 2016;23:170-9. [PMID: 26436722 DOI: 10.1111/jvh.12477] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
110 Lin YY, Huang JF, Liu SF, Yu ML, Tsai CH, Yang JF, Lin IL, Dai CY, Lin ZY, Chen SC, Chang WY, Chuang WL. Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA. Scand J Infect Dis 2009;41:614-8. [PMID: 19360504 DOI: 10.1080/00365540902875073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
111 Ridruejo E, Marciano S, Galdame O, Reggiardo MV, Muñoz AE, Adrover R, Cocozzella D, Fernandez N, Estepo C, Mendizábal M, Romero GA, Levi D, Schroder T, Paz S, Fainboim H, Mandó OG, Gadano AC, Silva MO. Relapse rates in chronic hepatitis B naïve patients after discontinuation of antiviral therapy with entecavir. J Viral Hepat 2014;21:590-6. [DOI: 10.1111/jvh.12200] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
112 Tan Z, Yin Y, Zhou J, Wu L, Xu C, Hou H. Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: Outcomes of telbivudine treatment during pregnancy. Medicine (Baltimore) 2016;95:e4847. [PMID: 27749537 DOI: 10.1097/MD.0000000000004847] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 3.4] [Reference Citation Analysis]
113 Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol. 2010;25:892-898. [PMID: 20546442 DOI: 10.1111/j.1440-1746.2009.06161.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
114 Ko SY, Kim BK, Kwon SY, Kim KH, Kim JH, Choe WH, Lee CH. Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World J Gastroenterol 2012; 18(44): 6437-6446 [PMID: 23197889 DOI: 10.3748/wjg.v18.i44.6437] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
115 Xiao C, Qin B, Chen L, Liu H, Zhu Y, Lu X. Preactivation of the interferon signalling in liver is correlated with nonresponse to interferon alpha therapy in patients chronically infected with hepatitis B virus. J Viral Hepat. 2012;19:e1-10. [PMID: 22239505 DOI: 10.1111/j.1365-2893.2011.01471.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
116 Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis 2017;76:1051-6. [PMID: 27934678 DOI: 10.1136/annrheumdis-2016-209973] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
117 Sun X, Qin W, Zhou R, Wang L, Li Y, Zhao L. Effect of conventional interferon-α in patients with HBeAg-positive chronic hepatitis B: a systematic review and meta-analysis: Conventional interferon-α for HBeAg-positive chronic hepatitis B. Journal of Evidence-Based Medicine 2010;3:220-5. [DOI: 10.1111/j.1756-5391.2010.01100.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
118 McKeage K, Keam SJ. Telbivudine: a review of its use in compensated chronic hepatitis B. Drugs. 2010;70:1857-1883. [PMID: 20836578 DOI: 10.2165/11204330-000000000-00000] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
119 Song XG, Bian PF, Yu SL, Zhao XH, Xu W, Bu XH, Li X, Ma LX. Expression of hepatitis B virus 1.3-fold genome plasmid in an SV40 T-antigen-immortalized mouse hepatic cell line. World J Gastroenterol 2013; 19(44): 8020-8027 [PMID: 24307795 DOI: 10.3748/wjg.v19.i44.8020] [Reference Citation Analysis]
120 Chien R, Liaw Y. Current treatment of chronic HBV infection: An Asian-Pacific perspective. Curr hepatitis rep 2009;8:154-60. [DOI: 10.1007/s11901-009-0022-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
121 Wei Q, Xu X, Ling Q, Zhou B, Zheng SS. Perioperative antiviral therapy for chronic hepatitis B-related hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12:251-255. [PMID: 23742769 DOI: 10.1016/s1499-3872(13)60041-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
122 Tong MJ, Huynh TT, Siripongsakun S, Chang PW, Tong LT, Ha YP, Mena EA, Weissman MF. Predicting clinical outcomes in patients with HBsAg-positive chronic hepatitis. Hepatol Int 2015;9:567-77. [PMID: 26219830 DOI: 10.1007/s12072-015-9651-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
123 Etzion O, Ghany MG. Screening for hepatitis B virus to prevent viral reactivation - who and when? Clinical Liver Disease. 2015;5:47-50. [PMID: 31040948 DOI: 10.1002/cld.458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
124 Hu YC, Liu H, Liu XY, Ma LN, Guan YH, Luo X, Ding XC. Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2017; 23(41): 7425-7432 [PMID: 29151696 DOI: 10.3748/wjg.v23.i41.7425] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
125 Park SH, Kim CH, Kim DJ, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB. Development and validation of a model to predict advanced fibrosis in chronic hepatitis B virus-infected patients with high viral load and normal or minimally raised ALT. Dig Dis Sci. 2011;56:1828-1834. [PMID: 21086167 DOI: 10.1007/s10620-010-1477-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
126 Han M, Li Y, Wu W, Zhang Y, Yan W, Luo X, Ning Q. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection. Antiviral Research 2017;147:75-85. [DOI: 10.1016/j.antiviral.2017.10.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
127 Zuo S, Zuo X, Wang C, Ma Y, Zhang H, Li Z, Song L, Deng Z, Liu S. A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection. The Journal of Clinical Pharmacology 2015;55:288-97. [DOI: 10.1002/jcph.409] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
128 Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, Yang JY, Xu MQ. Postoperative aspartate aminotransferase to platelet ratio index change predicts prognosis for hepatocellular carcinoma. Medicine (Baltimore) 2016;95:e4160. [PMID: 27472685 DOI: 10.1097/MD.0000000000004160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
129 Guan R, Lui HF. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol. 2011;2011:918017. [PMID: 21994876 DOI: 10.4061/2011/918017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
130 Nguyen NH, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Lutchman GA, Nguyen MH. Safety and efficacy of entecavir in adefovir-experienced patients. J Gastroenterol Hepatol. 2015;30:43-50. [PMID: 25168842 DOI: 10.1111/jgh.12728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
131 Gane E. Posttransplant Prophylaxis Strategies for Hepatitis B: Prevention of Recurrent Hepatitis B. American Journal of Transplantation 2010;10:1721-2. [DOI: 10.1111/j.1600-6143.2010.03193.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
132 Han Y, Zhang Y, Mei Y, Wang Y, Liu T, Guan Y, Tan D, Liang Y, Yang L, Yi X. Analysis of hepatitis B virus genotyping and drug resistance gene mutations based on massively parallel sequencing. Journal of Virological Methods 2013;193:341-7. [DOI: 10.1016/j.jviromet.2013.06.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
133 Kobayashi M, Hosaka T, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Kawamura Y, Kobayashi M, Saitoh S, Arase Y. Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up. J Gastroenterol. 2014;49:538-546. [PMID: 23783839 DOI: 10.1007/s00535-013-0821-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
134 Ahn SH, Chan HL, Chen PJ, Cheng J, Goenka MK, Hou J, Lim SG, Omata M, Piratvisuth T, Xie Q, Yim HJ, Yuen MF; APPROACH Working Group. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int. 2010;4:386-395. [PMID: 20305758 DOI: 10.1007/s12072-010-9163-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
135 Enomoto M, Morikawa H, Tamori A, Kawada N. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2014; 20(34): 12031-12038 [PMID: 25232240 DOI: 10.3748/wjg.v20.i34.12031] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
136 Wang ML, Chen EQ, Zhang DM, Du LY, Yan LB, Zhou TY, Lei XZ, Lei BJ, Lu JJ, Liao J, Tang H. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy. J Viral Hepat 2017;24 Suppl 1:21-8. [PMID: 29082645 DOI: 10.1111/jvh.12792] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
137 Jia W, Zhu MQ, Qi X, Wang T, Wen X, Chen PD, Fan QQ, Zhang WH, Zhang JM. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. Virol J 2019;16:61. [PMID: 31064399 DOI: 10.1186/s12985-019-1152-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
138 Kim BK, Ahn SH, Han K, Park JY, Han MS, Jo JH, Kim JK, Lee KS, Chon CY, Kim DY. Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. Digestion 2012;86:264-72. [DOI: 10.1159/000341507] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
139 Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, Schmutz G, Herrmann E. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011;55:1235-1240. [PMID: 21703180 DOI: 10.1016/j.jhep.2011.03.030] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 5.8] [Reference Citation Analysis]
140 Lu HY, Zhuang LW, Yu YY, Si CW. Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients. J Viral Hepat 2010;17 Suppl 1:59-65. [PMID: 20586935 DOI: 10.1111/j.1365-2893.2010.01272.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
141 Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, Lanza AG, Messina V, Iannacone C, Massetto B. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. 2012;56:1006-1011. [PMID: 22245886 DOI: 10.1016/j.jhep.2011.12.007] [Cited by in Crossref: 123] [Cited by in F6Publishing: 108] [Article Influence: 12.3] [Reference Citation Analysis]
142 Toy M, Hutton DW, So SK. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China. PLoS One 2015;10:e0139876. [PMID: 26536626 DOI: 10.1371/journal.pone.0139876] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
143 Tsai MC, Chen CH, Tseng PL, Hung CH, Chiu KW, Chang KC, Yen YH, Lin MT, Hu TH. Does Nucleos(t)ide Analogues Treatment Affect Renal Function in Chronic Hepatitis B Patients Who Have Already Decreased eGFR? A Longitudinal Study. PLoS One. 2016;11:e0149761. [PMID: 26964034 DOI: 10.1371/journal.pone.0149761] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
144 Gao S, Fan Y, Zhao J, Sun F, Han J, Zhao Z, Wang K. A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase ≤2 upper limit of normal. Liver Int 2014;34:e229-37. [DOI: 10.1111/liv.12344] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
145 Lee I, Yang S, Lee C, Su C, Wang Y, Lan K, Lin H, Hou M, Peng C, Huang Y. Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. The Journal of Infectious Diseases 2018;218:1075-84. [DOI: 10.1093/infdis/jiy272] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
146 Tanaka T, Benmousa A, Marquez M, Therapondos G, Renner EL, Lilly LB. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. Clin Transplant. 2012;26:E561-E569. [PMID: 23061767 DOI: 10.1111/ctr.12022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
147 Chen CH, Lee CM, Wang JH, Hu TH, Hung CH, Changchien CS, Lu SN. Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. Hepatol Int 2013;7:477-88. [PMID: 26201780 DOI: 10.1007/s12072-012-9381-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
148 Lok AS. Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? Hepatology 2010;51:1107-9. [DOI: 10.1002/hep.23496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
149 Peng H, Liu J, Yang M, Tong S, Yin W, Tang H, Hu P, Hu H, Ren H. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis. J Clin Pharmacol. 2014;54:189-200. [PMID: 24105676 DOI: 10.1002/jcph.181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
150 Chung HA, Kim JH, Hwang Y, Choi HS, Ko SY, Choe WH, Kwon SY. Noninvasive fibrosis marker can predict recurrence of hepatocellular carcinoma after radiofrequency ablation. Saudi J Gastroenterol 2016;22:57-63. [PMID: 26831608 DOI: 10.4103/1319-3767.173760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
151 Hsu CW, Chao YC, Lee CM, Chang TT, Chen YC. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24. BMC Gastroenterol 2012;12:178. [PMID: 23234302 DOI: 10.1186/1471-230X-12-178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
152 Ooi M, Teoh NC. Can long term therapy with oral nucleos(t)ide analogs influence the prognosis of chronic hepatitis B-related complications? J Gastroenterol Hepatol 2012;27:1541-3. [PMID: 22994430 DOI: 10.1111/j.1440-1746.2012.07221.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
153 Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol 2015; 21(46): 13087-13094 [PMID: 26673249 DOI: 10.3748/wjg.v21.i46.13087] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
154 Han Y, Chen Z, Hou R, Yan D, Liu C, Chen S, Li X, Du W. Expression of AIM2 is correlated with increased inflammation in chronic hepatitis B patients. Virol J. 2015;12:129. [PMID: 26290184 DOI: 10.1186/s12985-015-0360-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
155 Qi D, Yi JH, Shen GY. Antiviral therapy of chronic hepatitis B in women of childbearing age. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1634-1638 [DOI: 10.11569/wcjd.v19.i15.1634] [Reference Citation Analysis]
156 Zhu Z, Huang S, Zhang Y, Sun C, Tang Y, Zhao Q, Zhou Q, Ju W, He X. Bioinformatics analysis on multiple Gene Expression Omnibus datasets of the hepatitis B virus infection and its response to the interferon-alpha therapy. BMC Infect Dis 2020;20:84. [PMID: 31996147 DOI: 10.1186/s12879-019-4720-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
157 Viganò M, Lampertico P. Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue? Clin Liver Dis (Hoboken) 2013;2:21-3. [PMID: 30992815 DOI: 10.1002/cld.161] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
158 Ge GH, Ye Y, Zhou XB, Chen L, He C, Wen DF, Tan YW. Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients. World J Gastroenterol 2015; 21(28): 8653-8659 [PMID: 26229407 DOI: 10.3748/wjg.v21.i28.8653] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
159 García-Alonso FJ, Martín-Mateos RM, Moreira Vicente V. [Pharmacological treatment of acute hepatitis B]. Med Clin (Barc) 2012;138:633-7. [PMID: 22118973 DOI: 10.1016/j.medcli.2011.09.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
160 Lee HW, Park JY, Ahn SH. An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. Expert Rev Gastroenterol Hepatol 2016;10:177-86. [PMID: 26610256 DOI: 10.1586/17474124.2016.1125781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
161 Chen PC, Chen BH, Huang CH, Jeng WJ, Hsieh YC, Teng W, Chen YC, Ho YP, Sheen IS, Lin CY. Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and spontaneous bacterial peritonitis. Eur J Gastroenterol Hepatol 2019;31:1256-63. [PMID: 31498284 DOI: 10.1097/MEG.0000000000001481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
162 Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018;68:425-434. [PMID: 29108132 DOI: 10.1002/hep.29640] [Cited by in Crossref: 100] [Cited by in F6Publishing: 88] [Article Influence: 25.0] [Reference Citation Analysis]
163 Xie Q, Hu X, Zhang Y, Jiang X, Li X, Li J. Decreasing hepatitis B viral load is associated with a risk of significant liver fibrosis in hepatitis B e antigen positive chronic hepatitis B. J Med Virol. 2014;86:1828-1837. [PMID: 25145769 DOI: 10.1002/jmv.24000] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
164 Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Batrla-Utermann R, Wang LY, You SL, Hsiao CK, Chen PJ, Chen CJ;  R. E.V.E.A.L.-HBV Study Group. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut. 2014;63:1648-1657. [PMID: 24225939 DOI: 10.1136/gutjnl-2013-305785] [Cited by in Crossref: 103] [Cited by in F6Publishing: 90] [Article Influence: 11.4] [Reference Citation Analysis]
165 Tanwar S, Dusheiko G. Is There Any Value to Hepatitis B Virus Genotype Analysis? Curr Gastroenterol Rep 2012;14:37-46. [DOI: 10.1007/s11894-011-0233-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
166 Visram A, Chan KK, McGee P, Boro J, Hicks LK, Feld JJ. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. PLoS One. 2015;10:e0120749. [PMID: 25875198 DOI: 10.1371/journal.pone.0120749] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
167 Yuen MF, Lai CL. Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol. 2011;26 Suppl 1:138-143. [PMID: 21199525 DOI: 10.1111/j.1440-1746.2010.06545.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 9.4] [Reference Citation Analysis]
168 Yan LB, Chen EQ, Bai L, Du LY, Chen LL, Liao J, He M, Tang H. Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load. Clin Res Hepatol Gastroenterol 2015;39:366-72. [PMID: 25468548 DOI: 10.1016/j.clinre.2014.09.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
169 Zobeiri M. Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat. 2013;2013:259148. [PMID: 23533738 DOI: 10.1155/2013/259148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
170 Zeng T, Xu H, Liu JY, Lei Y, Zhong S, Zhou Z. Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis. J Clin Pharmacol 2014;54:959-67. [PMID: 24964070 DOI: 10.1002/jcph.351] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
171 Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1323-1331. [PMID: 21050234 DOI: 10.1111/j.1365-2036.2010.04474.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 6.9] [Reference Citation Analysis]
172 Massoumi H, Martin P, Tan H. Management of chronic hepatitis B: . European Journal of Gastroenterology & Hepatology 2011;23:642-50. [DOI: 10.1097/meg.0b013e3283474add] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
173 Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Huang HJ. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat. 2013;20:e3-10. [PMID: 23490387 DOI: 10.1111/jvh.12010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
174 Gao YJ, Zhang M, Jin B, Meng FP, Ma XM, Liu ZW, Su HB, Zhao JM, Li HW. Clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients. J Gastroenterol Hepatol. 2014;29:554-560. [PMID: 24117714 DOI: 10.1111/jgh.12404] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
175 Xu J, Wang J, He S, Su X, Zhong Z, Zhong W, Yan L, Huang S, Yang J, Gao R, Zhang J, Zeng J, Zhang D, Li T, Zhang S, Ge S, Zhang J, Xia N. Accurate nucleic acid quantification in a single sample tube without the need for calibration. Anal Chim Acta 2021;1167:338599. [PMID: 34049623 DOI: 10.1016/j.aca.2021.338599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Wu QJ, Lv WL, Li JM, Zhang TT, Zhou WH, Zhang Q, Wang JC, Wang QN, Zhang RX, Zhao X, Chen ST, Liu S, Li GH, Cao ZM, Xu L, Chen J. Efficacy and safety of YinQiSanHuang-antiviral decoction in chronic hepatitis B: study protocol for a randomized, placebo-controlled, double-blinded trial. Trials 2020;21:482. [PMID: 32503608 DOI: 10.1186/s13063-020-04395-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
177 Cheng JL, Wang XL, Yang SG, Zhao H, Wu JJ, Li LJ. Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patients. World J Gastroenterol 2017; 23(15): 2802-2810 [PMID: 28487618 DOI: 10.3748/wjg.v23.i15.2802] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
178 Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31:1095-1103. [PMID: 20180785 DOI: 10.1111/j.1365-2036.2010.04276.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 7.3] [Reference Citation Analysis]
179 Fung J, Lai C, Young J, Wong DK, Yuen J, Seto W, Yuen M. Stability of hepatitis B surface antigen over time: Implications for studies using stored sera. J Med Virol 2011;83:1900-4. [DOI: 10.1002/jmv.22171] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
180 Yi RT, Niu YH, Liu HL, Zhang TY, Yang YC, Zhang Y, Yin DL, Chen TY, Zhao YR. Natural Killer Group 2A Expressed on Both Peripheral CD3-CD56+NK Cells and CD3+CD8+T Cells Plays a Pivotal Negative Regulatory Role in the Progression of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. J Interferon Cytokine Res 2016;36:689-97. [PMID: 27828717 DOI: 10.1089/jir.2015.0166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
181 Wang GQ, Ding YP, Dong YH. Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients. J Viral Hepat. 2013;20 Suppl 1:9-17. [PMID: 23458520 DOI: 10.1111/jvh.12059] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
182 Lee HW, Kang W, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park YN, Han KH. Red cell volume distribution width-to-platelet ratio in assessment of liver fibrosis in patients with chronic hepatitis B. Liver Int. 2016;36:24-30. [PMID: 25966326 DOI: 10.1111/liv.12868] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
183 Chang BW, Kaung A, Robbins L, Tran TT. Hepatitis B: Working Towards a Cure. Curr Gastroenterol Rep 2015;17:35. [PMID: 26275560 DOI: 10.1007/s11894-015-0460-2] [Reference Citation Analysis]
184 Tsai M, Chen C, Hu T, Lu S, Lee C, Wang J, Hung C. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. Journal of the Formosan Medical Association 2017;116:512-21. [DOI: 10.1016/j.jfma.2016.08.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
185 Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33. [PMID: 19669245 DOI: 10.1007/s12072-009-9140-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 6.1] [Reference Citation Analysis]
186 Zhang C, Ke W, Gao Y, Zhou S, Liu L, Ye X, Yao Z, Yang Y. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China. Clin Drug Investig 2015;35:197-209. [PMID: 25672930 DOI: 10.1007/s40261-015-0273-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
187 Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology. 2009;49:1859-1867. [PMID: 19378345 DOI: 10.1002/hep.22878] [Cited by in Crossref: 111] [Cited by in F6Publishing: 100] [Article Influence: 8.5] [Reference Citation Analysis]
188 Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology. 2011;53:2121-2129. [PMID: 21503943 DOI: 10.1002/hep.24364] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
189 Sun W, Zhao S, Ma L, Hao A, Zhao B, Zhou L, Li F, Song M. Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission. BMC Gastroenterol 2017;17:51. [PMID: 28407735 DOI: 10.1186/s12876-017-0608-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
190 Poon RT, Cheung TT, Kwok PC, Lee AS, Li TW, Loke KL, Chan SL, Cheung MT, Lai TW, Cheung CC. Hong Kong consensus recommendations on the management of hepatocellular carcinoma. Liver Cancer. 2015;4:51-69. [PMID: 26020029 DOI: 10.1159/000367728] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
191 Stevens K, Palmo T, Wangchuk T, Solomon S, Dierberg K, Hoffmann CJ. Hepatitis B prevalence and treatment needs among Tibetan refugees residing in India. J Med Virol 2016;88:1357-63. [PMID: 26822932 DOI: 10.1002/jmv.24488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
192 Jeng W, Sheen I, Chen Y, Hsu C, Chien R, Chu C, Liaw Y. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888-96. [DOI: 10.1002/hep.26549] [Cited by in Crossref: 150] [Cited by in F6Publishing: 141] [Article Influence: 16.7] [Reference Citation Analysis]
193 Geng Y, Wang X, Lu X, Wu X, Xu N, Han L, Xu J. Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy. Medicine (Baltimore) 2016;95:e2657. [PMID: 26844490 DOI: 10.1097/MD.0000000000002657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
194 Zeng DW, Zhu YY, Huang Q, Zhang JM, Wu YL, Dong J, Jiang JJ, Liu YR. Hepatitis B surface antigen in late hepatitis B infection. J Med Virol. 2015;87:380-387. [PMID: 25604455 DOI: 10.1002/jmv.24078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
195 Yang SH, Hsu C, Cheng AL, Kuo SH. Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases. World J Hematol 2014; 3(2): 29-43 [DOI: 10.5315/wjh.v3.i2.29] [Reference Citation Analysis]
196 Martín Mateos RM, Moreira Vicente VF, Tavío Hernández E, Cuño Roldán JL, Téllez Villajos L, Aicart Ramos M, Arribas Anta J, Zaera de la Fuente C, Albillos Martínez A. [Is it possible to stop treatment with nucleos(t)ide analogs in patients with e-antigen negative chronic hepatitis B? Experience and new expectations]. Gastroenterol Hepatol 2015;38:305-12. [PMID: 25636371 DOI: 10.1016/j.gastrohep.2014.12.001] [Reference Citation Analysis]
197 Berg T, Benhamou Y, Calleja JL, Levrero M, Johnson W, Ellis N. A survey of chronic hepatitis B patient management practices in the European Union. J Viral Hepat. 2010;17:624-630. [PMID: 20487257 DOI: 10.1111/j.1365-2893.2010.01318.x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
198 Perry CM, Simpson D. Tenofovir disoproxil fumarate: in chronic hepatitis B. Drugs. 2009;69:2245-2256. [PMID: 19852527 DOI: 10.2165/10482940-000000000-00000] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
199 Qiu N, Li R, Yu JG, Yang W, Zhang W, An Y, Li T, Liu XE, Zhuang H. Comparison of Abbott and Da-an real-time PCR for quantitating serum HBV DNA. World J Gastroenterol 2014; 20(33): 11762-11769 [PMID: 25206280 DOI: 10.3748/wjg.v20.i33.11762] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
200 Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol. 2011;26 Suppl 1:131-137. [PMID: 21199524 DOI: 10.1111/j.1440-1746.2010.06544.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
201 Wu CC, Chen YS, Cao L, Chen XW, Lu MJ. Hepatitis B virus infection: Defective surface antigen expression and pathogenesis. World J Gastroenterol 2018; 24(31): 3488-3499 [PMID: 30131655 DOI: 10.3748/wjg.v24.i31.3488] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
202 Mekky MA. To treat or not to treat the "immunotolerant phase" of hepatitis B infection: A tunnel of controversy. World J Hepatol 2014; 6(4): 226-229 [PMID: 24799991 DOI: 10.4254/wjh.v6.i4.226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
203 He L, Xia Z, Shen J, Zhang X, Peng W, Li C, Wen T. The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection. Medicine (Baltimore) 2019;98:e14386. [PMID: 30732177 DOI: 10.1097/MD.0000000000014386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Sayan M, Dogan C. Genotype/subgenotype distribution of hepatitis B virus among hemodialysis patients with chronical hepatitis B. Annals of Hepatology 2012;11:849-54. [DOI: 10.1016/s1665-2681(19)31409-7] [Cited by in Crossref: 6] [Article Influence: 0.6] [Reference Citation Analysis]
205 Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol. 2013;48:999-1005. [PMID: 23338486 DOI: 10.1007/s00535-012-0742-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
206 Chakravarty R. Role of molecular diagnostics in the management of viral hepatitis B. Expert Opin Med Diagn 2012;6:395-406. [PMID: 23480805 DOI: 10.1517/17530059.2012.690391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
207 Pan X, Zhang K, Yang X, Liang J, Sun H, Li X, Zou Y, Xu Q, An G, Li G. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One. 2013;8:e68568. [PMID: 23844222 DOI: 10.1371/journal.pone.0068568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
208 Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther 2018;47:1181-200. [PMID: 29479728 DOI: 10.1111/apt.14577] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
209 Maklad S, Reyad EM, William EA, Abouzeid A. Efficacy and Safety of Entecavir 0. 5 mg in Treating Naive Chronic Hepatitis B Virus Patients in Egypt: Five Years of Real Life Experience. Gastroenterology Res 2018;11:138-44. [PMID: 29707081 DOI: 10.14740/gr965w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
210 Chan HL, Wong VW. Hepatitis B. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 540-63. [DOI: 10.1016/b978-1-4377-0881-3.00030-9] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
211 Liu J, Chen T, Zhao Y. Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment. J Viral Hepat 2017;24 Suppl 1:6-11. [PMID: 29082653 DOI: 10.1111/jvh.12787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Rijckborst V, Sonneveld MJ, Janssen HL. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? Aliment Pharmacol Ther. 2011;33:501-513. [PMID: 21198707 DOI: 10.1111/j.1365-2036.2010.04555.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
213 Zeng DW, Zhang JM, Liu YR, Dong J, Jiang JJ, Zhu YY. A Retrospective Study on the Significance of Liver Biopsy and Hepatitis B Surface Antigen in Chronic Hepatitis B Infection. Medicine (Baltimore). 2016;95:e2503. [PMID: 26937895 DOI: 10.1097/md.0000000000002503] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
214 Chen E, Song X, Wang Y, Zhou T, Bai L, Liu L, Liu C, Cheng X, Tang H. Construction of a highly-active, liver-specific transcriptional regulatory element through combination of the albumin promoter and α-fetoprotein enhancer. Plasmid 2011;65:125-31. [DOI: 10.1016/j.plasmid.2010.11.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
215 Li J, Zhang D, Zhang X. The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report. Infect Drug Resist 2021;14:1013-7. [PMID: 33758517 DOI: 10.2147/IDR.S295060] [Reference Citation Analysis]
216 Chang TT. On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol Int 2009;3 Suppl 1:16-23. [PMID: 19669242 DOI: 10.1007/s12072-009-9143-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
217 Li XY, You X, Jie YS, Lin GL, Wu YK, Huang MX, Zhang M, Li ZY, Xie DY, Gao ZL, Chong YT. Entecavir Combined With Adefovir Ameliorates Patients With Chronic Hepatitis B Who Fail to Respond to Nucleotide (Acid) Analog Monotherapy. Am J Ther 2017;24:e250-8. [PMID: 25923228 DOI: 10.1097/MJT.0000000000000262] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
218 Liu F, Zou F, Wang X, Hu H, Hu P, Ren H. A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study. Virol J 2015;12:179. [PMID: 26527281 DOI: 10.1186/s12985-015-0409-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
219 Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 2011;31 Suppl 1:111-116. [PMID: 21205147 DOI: 10.1111/j.1478-3231.2010.02399.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 7.1] [Reference Citation Analysis]
220 Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, Lee CM. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol 2014;61:515-22. [PMID: 24798617 DOI: 10.1016/j.jhep.2014.04.029] [Cited by in Crossref: 101] [Cited by in F6Publishing: 97] [Article Influence: 12.6] [Reference Citation Analysis]
221 Liu J, Hu HH, Lee MH, Korenaga M, Jen CL, Batrla-Utermann R, Lu SN, Wang LY, Mizokami M, Chen CJ, Yang HI. Serum Levels of M2BPGi as Short-Term Predictors of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients. Sci Rep. 2017;7:14352. [PMID: 29085039 DOI: 10.1038/s41598-017-14747-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
222 Hu DJ, Xing J, Tohme RA, Liao Y, Pollack H, Ward JW, Holmberg SD. Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009-2010. Hepatology. 2013;58:856-862. [PMID: 23359276 DOI: 10.1002/hep.26286] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
223 Dai J, Sun S, Peng J, Cao H, Zheng N, Fang J, Li Q, Jiang J, Zhang Y, Hu Y. Exploration of macro-micro biomarkers for dampness-heat syndrome differentiation in different diseases. Evid Based Complement Alternat Med 2013;2013:706762. [PMID: 23710231 DOI: 10.1155/2013/706762] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
224 Yu W, Wang Y, Shen C, Ji R, Zhang L, Zhao X, Su M, Zhang Y, He W, Cao J, Hao Y, Chen S, Zhao C. Predictors of HBeAg seroconversion after long-term nucleos(t)ide analogues treatment for chronic hepatitis B: a multicenter study in real clinical setting. Braz J Infect Dis 2017;21:213-8. [PMID: 28351603 DOI: 10.1016/j.bjid.2017.03.001] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
225 Singal AK, Salameh H, Kuo YF, Fontana RJ. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther. 2013;38:98-106. [PMID: 23713520 DOI: 10.1111/apt.12344] [Cited by in Crossref: 97] [Cited by in F6Publishing: 89] [Article Influence: 10.8] [Reference Citation Analysis]
226 Kennedy M, Alexopoulos SP. Hepatitis B virus infection and liver transplantation: . Current Opinion in Organ Transplantation 2010;15:310-5. [DOI: 10.1097/mot.0b013e32833991f8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
227 Jin YJ, Shim JH, Chung YH, Kim JA, Choi JG, Park WH, Lee D, Kim SE, Lee YS, Kim SH, Yang SH. HLA-DRB1*010101 allele is closely associated with poor virological response to lamivudine therapy in patients with chronic hepatitis B. Digestion 2011;84 Suppl 1:35-42. [PMID: 22156484 DOI: 10.1159/000333783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
228 Baqai SF, Proudfoot J, Yi DH, Mangahas M, Gish RG. High rate of core promoter and precore mutations in patients with chronic hepatitis B. Hepatol Int. 2015;9:209-217. [PMID: 25788186 DOI: 10.1007/s12072-014-9598-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
229 Kim YJ, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, Cho SW. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients. Clin Mol Hepatol. 2013;19:300-304. [PMID: 24133668 DOI: 10.3350/cmh.2013.19.3.300] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
230 Kim BG, Jung SW, Kim EH, Kim JH, Park JH, Sung SJ, Park BR, Kim M, Kim CJ, Lee BU, Park JH, Jeong ID, Bang S, Shin JW, Park NH. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir: Tenofovir in multidrug resistant hepatitis B. J Gastroenterol Hepatol 2015;30:1514-21. [DOI: 10.1111/jgh.12993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
231 Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
232 Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009;18:1655-1666. [PMID: 19852566 DOI: 10.1517/13543780903241599] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
233 Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int. 2010;4:414-422. [PMID: 20305760 DOI: 10.1007/s12072-009-9162-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
234 Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980-988. [PMID: 24368224 DOI: 10.1053/j.gastro.2013.12.028] [Cited by in Crossref: 118] [Cited by in F6Publishing: 108] [Article Influence: 13.1] [Reference Citation Analysis]
235 Lin B, Ha NB, Liu A, Trinh HN, Nguyen HA, Nguyen KK, Ahmed A, Keeffe EB, Garcia RT, Garcia G. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol. 2013;28:855-860. [PMID: 23278507 DOI: 10.1111/jgh.12108] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
236 Bang KB, Kim HJ. Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol 2014; 20(33): 11641-11649 [PMID: 25206270 DOI: 10.3748/wjg.v20.i33.11641] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
237 Jeon SR, Jang JY, Jeong SW, Park SH, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Moon JH, Kim HS, Lee JS, Kim BS. HBV DNA loss within 24 weeks predicts late viral breakthrough in chronic hepatitis B. Korean J Gastroenterol 2011;58:25-30. [PMID: 21778800 DOI: 10.4166/kjg.2011.58.1.25] [Reference Citation Analysis]
238 Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, Liu CY, Yang MH, Tzeng CH, Lee PC, Lin HC, Lee SD. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765-2772. [PMID: 23775967 DOI: 10.1200/jco.2012.48.5938] [Cited by in Crossref: 221] [Cited by in F6Publishing: 91] [Article Influence: 24.6] [Reference Citation Analysis]
239 Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag 2009;5:789-98. [PMID: 19851526 DOI: 10.2147/tcrm.s5318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
240 Wang C, Fan R, Sun J, Hou J. Prevention and management of drug resistant hepatitis B virus infections: Facing antiviral drug resistance. Journal of Gastroenterology and Hepatology 2012;27:1432-40. [DOI: 10.1111/j.1440-1746.2012.07198.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
241 Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saito S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol. 2012;47:1022-1029. [PMID: 22370817 DOI: 10.1007/s00535-012-0561-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
242 Cheung MC, Agarwal K. Liver abnormalities in the immunosuppressed. Best Practice & Research Clinical Gastroenterology 2013;27:597-618. [DOI: 10.1016/j.bpg.2013.06.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
243 Tong MJ, Hsu L, Chang PW, Blatt LM. Evaluation of current treatment recommendations for chronic hepatitis B: A 2011 update: Treatment guidelines for hepatitis B. Journal of Gastroenterology and Hepatology 2011;26:829-35. [DOI: 10.1111/j.1440-1746.2011.06623.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
244 Lee HW, Kwon JC, Oh IS, Chang HY, Cha YJ, Choi IS, Kim HJ. Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response. Antimicrob Agents Chemother 2015;59:5348-56. [PMID: 26100697 DOI: 10.1128/AAC.01017-15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
245 Liu F, Yu DM, Huang SY, Yu JL, Zhang DH, Gong QM, Zhang XX. Clinical implications of evolutionary patterns of homologous, full-length hepatitis B virus quasispecies in different hosts after perinatal infection. J Clin Microbiol 2014;52:1556-65. [PMID: 24574300 DOI: 10.1128/JCM.03338-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
246 McMahon BJ, Bulkow L, Simons B, Zhang Y, Negus S, Homan C, Spradling P, Teshale E, Lau D, Snowball M. Relationship Between Level of Hepatitis B Virus DNA and Liver Disease: A Population-based Study of Hepatitis B e Antigen-Negative Persons With Hepatitis B. Clin Gastroenterol Hepatol. 2014;12:701-706.e3. [PMID: 24035774 DOI: 10.1016/j.cgh.2013.09.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
247 Ma L, Alla NR, Li X, Mynbaev OA, Shi Z. Mother-to-child transmission of HBV: review of current clinical management and prevention strategies: Mother-to-child transmission of HBV. Rev Med Virol 2014;24:396-406. [DOI: 10.1002/rmv.1801] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
248 Zhang Y, Feng Y, Cao B, Tian Q. The effect of small intestinal bacterial overgrowth on minimal hepatic encephalopathy in patients with cirrhosis. Arch Med Sci. 2016;12:592-596. [PMID: 27279853 DOI: 10.5114/aoms.2015.55675] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
249 Yao J, Zhou L, Hua X, Kong M, Chen Y, Duan Z. Effects of nucleos(t)ide analogs on body composition in HBV-infected men: An age- and BMI-matched, cross-sectional study. Nutrition 2016;32:1206-10. [PMID: 27283043 DOI: 10.1016/j.nut.2016.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
250 Lian JS, Zeng LY, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19(37): 6278-6283 [PMID: 24115827 DOI: 10.3748/wjg.v19.i37.6278] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
251 Inoue T, Tanaka Y. Hepatitis B virus and its sexually transmitted infection - an update. Microb Cell 2016;3:420-37. [PMID: 28357379 DOI: 10.15698/mic2016.09.527] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
252 Lv GC, Ma WJ, Ying LJ, Jin X, Zheng L, Yang YD. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. World J Gastroenterol 2010; 16(32): 4095-4099 [PMID: 20731026 DOI: 10.3748/wjg.v16.i32.4095] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
253 Andreani T. HBV-carriers: When is monitoring and surveillance sufficient? (point of view). Clin Res Hepatol Gastroenterol 2011;35:813-8. [PMID: 21821479 DOI: 10.1016/j.clinre.2011.06.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
254 Kwon JH, Jang JW, Lee S, Lee J, Chung KW, Lee YS, Choi JY. Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B. J Viral Hepat. 2012;19:e41-e47. [PMID: 22239525 DOI: 10.1111/j.1365-2893.2011.01509.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
255 Lim YS, Byun KS, Yoo BC, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 2016;65:852-860. [PMID: 25596179 DOI: 10.1136/gutjnl-2014-308353] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 7.9] [Reference Citation Analysis]
256 Segovia MC, Chacra W, Gordon SC. Adefovir dipivoxil in chronic hepatitis B: history and current uses. Expert Opin Pharmacother 2012;13:245-54. [PMID: 22242973 DOI: 10.1517/14656566.2012.649727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
257 Wang CT, Zhang YF, Sun BH, Dai Y, Zhu HL, Xu YH, Lu MJ, Yang DL, Li X, Zhang ZH. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients. World J Gastroenterol 2015; 21(18): 5668-5676 [PMID: 25987794 DOI: 10.3748/wjg.v21.i18.5668] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
258 Huang Z, Zhao Z, Zheng Y, Peng L, Lin C, Deng H, Gao Z. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study. J Viral Hepat 2013;20:52-7. [DOI: 10.1111/jvh.12064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
259 Wang S, Han Q, Zhang G, Zhang N, Li Z, Chen J, Lv Y, Li N, Xing F, Tian N, Zhu Q, Liu Z. CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase. Int Immunopharmacol 2011;11:406-11. [PMID: 21182997 DOI: 10.1016/j.intimp.2010.12.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
260 Fung J, Seto WK, Lai CL, Yuen J, Wong DK, Yuen MF. Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy. J Hepatol. 2011;54:195-200. [PMID: 21056499 DOI: 10.1016/j.jhep.2010.06.031] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
261 Song MJ, Song DS, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HJ. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012; 18(43): 6277-6283 [PMID: 23180949 DOI: 10.3748/wjg.v18.i43.6277] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
262 Chen YH, Lu SN, Wang JH, Hung CH, Hu TH, Chen CH. Pre-S/Surface and Core Promoter/Precore Mutations in Chronic Hepatitis B Patients with Severe Acute Exacerbation. Dig Dis Sci 2019;64:2563-9. [PMID: 30835025 DOI: 10.1007/s10620-019-05571-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Cheng CP, Lee PF, Liu WC, Wu IC, Chin CY, Chang TT, Tseng VS. Analysis of precore/core covariances associated with viral kinetics and genotypes in hepatitis B e antigen-positive chronic hepatitis B patients. PLoS One 2012;7:e32553. [PMID: 22384271 DOI: 10.1371/journal.pone.0032553] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
264 Lee IC, Huang YH, Chu CJ, Lee PC, Lin HC, Lee SD. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc. 2010;73:156-160. [PMID: 20231001 DOI: 10.1016/s1726-4901(10)70031-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
265 Ferrante ND, Lo Re V 3rd. Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection. Curr HIV/AIDS Rep. 2020;17:405-414. [PMID: 32607773 DOI: 10.1007/s11904-020-00508-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
266 Lawandi A, Cheng MP, Lee TC. Hepatitis B testing practices at a tertiary care centre and their associated costs: A retrospective analysis. PLoS One 2019;14:e0219347. [PMID: 31283801 DOI: 10.1371/journal.pone.0219347] [Reference Citation Analysis]
267 Guo H, Zhu B, Li S, Li J, Shen Z, Zheng Y, Zhao W, Tan D, Wu J, Zhang X, Jiang Q, Qi X, Mao R, Yu X, Su Z, Zhang J. Development and Validation of a Novel Model to Predict Liver Histopathology in Patients with Chronic Hepatitis B. Biomed Res Int 2019;2019:1621627. [PMID: 30937309 DOI: 10.1155/2019/1621627] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
268 Di Marco V, Craxì A. Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev Anti Infect Ther 2009;7:281-91. [PMID: 19344242 DOI: 10.1586/eri.09.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
269 Xiao L, Xian J, Li Y, Geng A, Yang X, Han L, Xu H. Parameters associated with significant liver histological changes in patients with chronic hepatitis B. ISRN Gastroenterol 2014;2014:913890. [PMID: 24616815 DOI: 10.1155/2014/913890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
270 Leung NW, Herrmann E, Lau GK, Chan HL, So TM, Zeuzem S, Dong Y, Trylesinski A, Naoumov NV. Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B. Infect Dis Ther 2014;3:191-202. [PMID: 25228496 DOI: 10.1007/s40121-014-0039-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
271 Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir vs adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology. 2011;54:91-100. [PMID: 21503940 DOI: 10.1002/hep.24361] [Cited by in Crossref: 143] [Cited by in F6Publishing: 130] [Article Influence: 13.0] [Reference Citation Analysis]
272 Chen C, Lee W, Yang H, Chang H, Jen C, Iloeje UH, Su J, Hsiao CK, Wang L, You S, Lu S, Chen C. Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma. Gastroenterology 2011;141:1240-1248.e2. [DOI: 10.1053/j.gastro.2011.06.036] [Cited by in Crossref: 152] [Cited by in F6Publishing: 142] [Article Influence: 13.8] [Reference Citation Analysis]
273 Ng CJ, Low WY, Wong LP, Sudin MR, Mohamed R. Uncovering the experiences and needs of patients with chronic hepatitis B infection at diagnosis: a qualitative study. Asia Pac J Public Health 2013;25:32-40. [PMID: 21807630 DOI: 10.1177/1010539511413258] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
274 Mao QG, Pan JS, Fang KN, Zhang RM, Hong QY, Song MN, Zhu JP, Huang WQ, Chen LM, Hong MZ. Precise prediction model and simplified scoring system for sustained combined response to interferon-α. World J Gastroenterol 2010; 16(27): 3465-3471 [PMID: 20632453 DOI: 10.3748/wjg.v16.i27.3465] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
275 Chan HL, Wong VW, Wong GL, Chim AM, Lai LH, Sung JJ. Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. J Clin Microbiol 2009;47:1830-6. [PMID: 19386857 DOI: 10.1128/JCM.00029-09] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
276 Zeng DW, Zhang JM, Liu YR, Dong J, Wu YL, Lin S, Jiang JJ, Zhu YY. A new model for predicting liver cirrhosis in chronic hepatitis B virus carriers with low serum alanine transaminase activity. Clin Res Hepatol Gastroenterol. 2014;38:727-734. [PMID: 25048838 DOI: 10.1016/j.clinre.2014.06.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
277 Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62-72. [PMID: 21254162 DOI: 10.1002/hep.23952] [Cited by in Crossref: 218] [Cited by in F6Publishing: 199] [Article Influence: 18.2] [Reference Citation Analysis]
278 Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52:454-461. [PMID: 20683945 DOI: 10.1002/hep.23722] [Cited by in Crossref: 170] [Cited by in F6Publishing: 155] [Article Influence: 14.2] [Reference Citation Analysis]
279 Chien R. On-treatment monitoring of chronic hepatitis B virus infection: An Asian-Pacific perspective: On-treatment monitoring of HBV infection. Journal of Gastroenterology and Hepatology 2010;25:852-7. [DOI: 10.1111/j.1440-1746.2010.06271.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
280 Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, Manns MP, Wedemeyer H, Naoumov NV. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010;52:1611-1620. [PMID: 20931556 DOI: 10.1002/hep.23905] [Cited by in Crossref: 153] [Cited by in F6Publishing: 149] [Article Influence: 12.8] [Reference Citation Analysis]
281 Chevaliez S, Rodriguez C, Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C. Gastroenterology. 2012;142:1303-1313.e1. [PMID: 22537437 DOI: 10.1053/j.gastro.2012.02.027] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 8.8] [Reference Citation Analysis]
282 Wong GL, Chan HL, Choi PC, Chan AW, Lo AO, Chim AM, Wong VW. Association between anthropometric parameters and measurements of liver stiffness by transient elastography. Clin Gastroenterol Hepatol 2013;11:295-302.e1-3. [PMID: 23022698 DOI: 10.1016/j.cgh.2012.09.025] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
283 Huang H, Sun Z, Pan H, Chen M, Tong Y, Zhang J, Chen D, Su X, Li L. Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B. Sci Rep 2016;6:30853. [PMID: 27498553 DOI: 10.1038/srep30853] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
284 Coffin CS, Lee SS. New paradigms in hepatitis B management: only diamonds are forever. Br Med Bull 2015;116:79-91. [PMID: 26377741 DOI: 10.1093/bmb/ldv039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
285 Liu H, Wang X, Wan G, Yang Z, Zeng H. Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis. Am J Med Sci 2014;347:131-8. [PMID: 23563307 DOI: 10.1097/MAJ.0b013e318286878d] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
286 Chen B, Ye B, Zhang J, Ying L, Chen Y. RDW to platelet ratio: a novel noninvasive index for predicting hepatic fibrosis and cirrhosis in chronic hepatitis B. PLoS One 2013;8:e68780. [PMID: 23874760 DOI: 10.1371/journal.pone.0068780] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 8.7] [Reference Citation Analysis]
287 Ren ZQ, Liu TC, Hou JY, Chen MJ, Chen ZH, Lin GF, Wu YS. A rapid and sensitive method based on magnetic beads for the detection of hepatitis B virus surface antigen in human serum. Luminescence. 2014;29:591-597. [PMID: 24136927 DOI: 10.1002/bio.2587] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
288 Sun YT, Zhang YX, Tang H, Mao Q, Wang XZ, Zhang LY, Chen H, Zhong YN, Lin SM, Zhang DZ. Clinical characteristics and current management of hepatitis B and C in China. World J Gastroenterol 2014; 20(37): 13582-13590 [PMID: 25309089 DOI: 10.3748/wjg.v20.i37.13582] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
289 Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther. 2011;34:344-352. [PMID: 21671967 DOI: 10.1111/j.1365-2036.2011.04738.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 8.3] [Reference Citation Analysis]
290 Chen BH, Tseng HJ, Chen WT, Chen PC, Ho YP, Huang CH, Lin CY. Comparing Eight Prognostic Scores in Predicting Mortality of Patients with Acute-On-Chronic Liver Failure Who Were Admitted to an ICU: A Single-Center Experience. J Clin Med. 2020;9. [PMID: 32443729 DOI: 10.3390/jcm9051540] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
291 Wong TC, Fung JY, Lo CM. Prevention of recurrent hepatitis B infection after liver transplantation. Hepatobiliary & Pancreatic Diseases International 2013;12:465-72. [DOI: 10.1016/s1499-3872(13)60074-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
292 Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B. J Pediatr Gastroenterol Nutr. 2012;55:648-652. [PMID: 22688509 DOI: 10.1097/mpg.0b013e318262a737] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
293 Lau GK. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int. 2010;30:512-520. [PMID: 20102511 DOI: 10.1111/j.1478-3231.2009.02198.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
294 Feng L, Sun K, Zhang J, Feng G, Zhao Y. A novel non-invasive index using AFP and APTT is associated with liver fibrosis in patients with chronic hepatitis B infection: a retrospective cohort study. BMJ Open 2015;5:e008032. [PMID: 26391629 DOI: 10.1136/bmjopen-2015-008032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
295 Edey M, Barraclough K, Johnson DW. Review article: Hepatitis B and dialysis. Nephrology (Carlton). 2010;15:137-145. [PMID: 20470270 DOI: 10.1111/j.1440-1797.2009.01268.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 7.2] [Reference Citation Analysis]
296 Son CY, Ryu HJ, Lee JM, Ahn SH, Kim DY, Lee MH, Han KH, Chon CY, Park JY. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir. Liver Int 2012;32:1179-85. [DOI: 10.1111/j.1478-3231.2012.02793.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
297 Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int. 2013;33:244-254. [PMID: 23295056 DOI: 10.1111/liv.12036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
298 Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 342-374.e17. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
299 Law ST, Lee MK, Lee AS, Tung Y, Li KK. Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy. J Dig Dis 2016;17:325-33. [PMID: 27085094 DOI: 10.1111/1751-2980.12349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
300 Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011;8:275-284. [PMID: 21423260 DOI: 10.1038/nrgastro.2011.33] [Cited by in Crossref: 171] [Cited by in F6Publishing: 165] [Article Influence: 15.5] [Reference Citation Analysis]
301 Jeon JW, Shin HP, Lee JI, Joo KR, Cha JM, Park JJ, Lim JU, Lim K, Kim S. Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B. Dig Dis Sci. 2012;57:1358-1365. [PMID: 22134785 DOI: 10.1007/s10620-011-1988-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
302 Patwardhan VR, Sengupta N, Bonder A, Lau D, Afdhal NH. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. Aliment Pharmacol Ther 2014;40:804-10. [PMID: 25109610 DOI: 10.1111/apt.12908] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
303 Sahin M, Karayakar F, Koksal AR, Yetim A, İyisoy MS, Şen İ, Alkım H, Alkım C, Colak T. Changes in Liver Tissue Trace Element Concentrations During Hepatitis B Viral Infection Treatment. Biol Trace Elem Res 2019;188:245-50. [PMID: 29926391 DOI: 10.1007/s12011-018-1414-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
304 Berg T, Zoulim F, Moeller B, Trinh H, Marcellin P, Chan S, Kitrinos KM, Dinh P, Flaherty JF Jr, McHutchison JG, Manns M. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol. 2014;60:715-722. [PMID: 24295873 DOI: 10.1016/j.jhep.2013.11.024] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]
305 Liang XE, Chen YP, Zhang Q, Dai L, Zhu YF, Hou JL. Dynamic evaluation of liver stiffness measurement to improve diagnostic accuracy of liver cirrhosis in patients with chronic hepatitis B acute exacerbation. J Viral Hepat. 2011;18:884-891. [PMID: 21062388 DOI: 10.1111/j.1365-2893.2010.01389.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
306 Ma M, He M, Liao L, Guo Y, Yu D, Xiong Z, Liu Y, Zeng P, Liao P. Molecular epidemiology and population dynamics of hepatitis B virus in Dianjiang County, Chongqing, China. Arch Virol 2014;159:117-24. [PMID: 23913187 DOI: 10.1007/s00705-013-1765-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
307 Aziz M, Aziz H, Waheed Y, Gill ML. Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. Viral Immunol 2018;31:632-8. [PMID: 30285571 DOI: 10.1089/vim.2018.0022] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
308 Wong GLH. Transient elastography: Kill two birds with one stone? World J Hepatol 2013; 5(5): 264-274 [PMID: 23717737 DOI: 10.4254/wjh.v5.i5.264] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 6.6] [Reference Citation Analysis]
309 Lee IC, Su CW, Lan KH, Wang YJ, Lee KC, Lin HC, Hou MC, Huang YH. Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B. J Formos Med Assoc 2021;120:1676-85. [PMID: 33339708 DOI: 10.1016/j.jfma.2020.12.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
310 Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, Cho JY, Shim SG, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Rhim H, Paik YH. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget 2016;7:47794-807. [PMID: 27329596 DOI: 10.18632/oncotarget.10026] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
311 Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422-430. [PMID: 20049753 DOI: 10.1002/hep.23327] [Cited by in Crossref: 397] [Cited by in F6Publishing: 376] [Article Influence: 33.1] [Reference Citation Analysis]
312 Shen T, Yan XM. Hepatitis B virus genetic mutations and evolution in liver diseases. World J Gastroenterol 2014; 20(18): 5435-5441 [PMID: 24833874 DOI: 10.3748/wjg.v20.i18.5435] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
313 Chong CCN, Wong GLH, Lai PBS. Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma. World J Gastroenterol 2014; 20(20): 6006-6012 [PMID: 24876723 DOI: 10.3748/wjg.v20.i20.6006] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
314 Piratvisuth T, Komolmit P, Chan HL, Tanwandee T, Sukeepaisarnjaroen W, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J, Zeuzem S, Manns M, Uddin A, Dong Y, Trylesinski A. Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy. Drugs Context 2016;5:212294. [PMID: 27403192 DOI: 10.7573/dic.212294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
315 Zhu Y, Qin B, Xiao C, Lu X, Chen L. Cell-type specific interferon stimulated gene staining in liver underlies response to interferon therapy in chronic HBV infected patients. Dig Dis Sci 2012;57:2355-61. [PMID: 22585383 DOI: 10.1007/s10620-012-2169-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
316 Thedja MD, Roni M, Harahap AR, Siregar NC, Ie SI, Muljono DH. Occult hepatitis B in blood donors in Indonesia: altered antigenicity of the hepatitis B virus surface protein. Hepatol Int. 2010;4:608-614. [PMID: 21063484 DOI: 10.1007/s12072-010-9203-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
317 Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol. 2010;52:791-799. [PMID: 20409606 DOI: 10.1016/j.jhep.2009.12.036] [Cited by in Crossref: 87] [Cited by in F6Publishing: 88] [Article Influence: 7.3] [Reference Citation Analysis]
318 Yu Y, Hou J, Omata M, Wang Y, Li L. Loss of HBsAg and antiviral treatment: from basics to clinical significance. Hepatol Int 2014;8:39-54. [PMID: 26202405 DOI: 10.1007/s12072-013-9495-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
319 Buti M, Morillas RM, Prieto M, Diago M, Pérez J, Solà R, Bonet L, Palau A, Testillano M, García-Samaniego J. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. Eur J Gastroenterol Hepatol. 2012;24:535-542. [PMID: 22382708 DOI: 10.1097/meg.0b013e3283511287] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
320 Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol Int. 2009;3:5-15. [PMID: 19763714 DOI: 10.1007/s12072-009-9149-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
321 Zhang X, Li C, Wen T, Yan L, Yang J, Tang H, Lu C. The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of HBV-Related HCC After Curative Resection. J Gastrointest Surg 2021;25:1419-29. [PMID: 32410175 DOI: 10.1007/s11605-020-04633-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
322 Chung GE, Lee JH, Kim YJ. Does antiviral therapy reduce complications of cirrhosis? World J Gastroenterol 2014; 20(23): 7306-7311 [PMID: 24966601 DOI: 10.3748/wjg.v20.i23.7306] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
323 Strasser SI. Drugs in Development for the Treatment of Chronic Hepatitis B. Curr Hepatitis Rep 2012;11:111-8. [DOI: 10.1007/s11901-012-0131-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
324 Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012;142:1360-1368.e1. [PMID: 22537444 DOI: 10.1053/j.gastro.2012.01.044] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 9.2] [Reference Citation Analysis]
325 Rajbhandari R, Chung RT. Treatment of Hepatitis B: A Concise Review. Clin Transl Gastroenterol 2016;7:e190. [PMID: 27628420 DOI: 10.1038/ctg.2016.46] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
326 Kose S, Tatar B, Gül S, Pala E. The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B. Acta Clin Belg 2016;71:244-9. [PMID: 27075801 DOI: 10.1080/17843286.2015.1118183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
327 McMahon BJ. Recent advances in managing hepatitis B. F1000 Med Rep 2010;2:11. [PMID: 20948875 DOI: 10.3410/M2-11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
328 Wong GL, Wong VW, Chim AM, Yiu KK, Chu SH, Li MK, Chan HL. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol 2011;26:300-5. [PMID: 21261720 DOI: 10.1111/j.1440-1746.2010.06510.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 99] [Article Influence: 8.9] [Reference Citation Analysis]
329 Zhu CW, Wang HY, Fang H. Antiviral therapy in patients with hepatitis B virus-related cirrhosis. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1592-1597 [DOI: 10.11569/wcjd.v19.i15.1592] [Reference Citation Analysis]
330 Lesmana CR, Jackson K, Lim SG, Sulaiman A, Pakasi LS, Gani RA, Hasan I, Sulaiman AS, Lesmana LA, Hammond R, Revill P, Locarnini S, Bowden SD. Clinical significance of hepatitis B virion and SVP productivity: relationships between intrahepatic and serum markers in chronic hepatitis B patients. United European Gastroenterol J 2014;2:99-107. [PMID: 24918014 DOI: 10.1177/2050640614525151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
331 Zhang TT, Ye J, Xia SL, Zhang YF, Su Q, Zhang ZH, Li X. Polymorphism of estrogen receptor alpha (ESR1) is associated with virological response to entecavir (ETV) in nucleoside-naïve adult patients with chronic hepatitis B. Infection 2013;41:371-8. [PMID: 23109139 DOI: 10.1007/s15010-012-0320-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
332 Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol. 2010;8:541-545. [PMID: 20298811 DOI: 10.1016/j.cgh.2010.02.023] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
333 Xu WS, Qiu XM, Ou QS, Liu C, Lin JP, Chen HJ, Lin S, Wang WH, Lin SR, Chen J. Red blood cell distribution width levels correlate with liver fibrosis and inflammation: a noninvasive serum marker panel to predict the severity of fibrosis and inflammation in patients with hepatitis B. Medicine (Baltimore). 2015;94:e612. [PMID: 25761184 DOI: 10.1097/md.0000000000000612] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
334 Pérez-Cameo C, Pons M, Esteban R. New therapeutic perspectives in HBV: when to stop NAs. Liver Int. 2014;34 Suppl 1:146-153. [PMID: 24373092 DOI: 10.1111/liv.12398] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
335 Chan HL, Wong GL, Tse CH, Chan HY, Wong VW. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis. 2011;204:408-414. [PMID: 21742839 DOI: 10.1093/infdis/jir283] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 7.1] [Reference Citation Analysis]
336 Hou JL, Xu D, Shi G, Wan M, Goodman Z, Tan D, Xie Q, Chen C, Wei L, Niu J, Wang Q, Ren H, Wang Y, Jia J, Bao W, Dong Y, Trylesinski A, Naoumov NV. Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B. Adv Ther 2015;32:727-41. [PMID: 26329749 DOI: 10.1007/s12325-015-0232-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
337 Chen CH, Chang CL, Chen KH, Cheng BC, Chen HH, Chiang JY, Sung PH, Yip HK. Level and Value of T Cell-derived Circulating Microparticles in Liver Cirrhosis Patients. In Vivo 2019;33:2265-72. [PMID: 31662566 DOI: 10.21873/invivo.11732] [Reference Citation Analysis]
338 Khamduang W, Gaudy-Graffin C, Ngo-Giang-Huong N, Jourdain G, Moreau A, Borkird T, Layangool P, Kamonpakorn N, Jitphiankha W, Kwanchaipanich R, Potchalongsin S, Lallemant M, Sirirungsi W, Goudeau A; Program for HIV Prevention and Treatment (PHPT) group. Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring. J Clin Virol 2013;58:415-21. [PMID: 23916828 DOI: 10.1016/j.jcv.2013.06.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
339 Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK;  REACH-B Working Group. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12:568-574. [PMID: 21497551 DOI: 10.1016/s1470-2045(11)70077-8] [Cited by in Crossref: 366] [Cited by in F6Publishing: 146] [Article Influence: 33.3] [Reference Citation Analysis]
340 Ren P, Cao Z, Mo R, Liu Y, Chen L, Li Z, Zhou T, Lu J, Liu Y, Guo Q, Chen R, Zhou H, Xiang X, Cai W, Wang H, Bao S, Xu Y, Gui H, Xie Q. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther 2018;18:1085-94. [PMID: 30182763 DOI: 10.1080/14712598.2018.1518423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
341 Jia W, Qi X, Ji YY, Xun YH, Wang H, Zhang WH, Yang JH, Wang JY, Zhu HX, Mao RC, Zhang JM. Low Serum Hepatitis B Surface Antigen Level Predicts Compensated Cirrhosis Caused by Chronic Hepatitis B in HBeAg Positive Patients in East China. Hepat Mon 2015;15:e29183. [PMID: 26322110 DOI: 10.5812/hepatmon.29183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
342 Wait S, Chen DS. Towards the eradication of hepatitis B in Taiwan. Kaohsiung J Med Sci 2012;28:1-9. [PMID: 22226055 DOI: 10.1016/j.kjms.2011.10.027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
343 Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol. 2012;57:508-514. [PMID: 22659518 DOI: 10.1016/j.jhep.2012.04.037] [Cited by in Crossref: 109] [Cited by in F6Publishing: 103] [Article Influence: 10.9] [Reference Citation Analysis]
344 Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan H, Sung JJ, Chan HL. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. Journal of Hepatology 2011;54:236-42. [DOI: 10.1016/j.jhep.2010.06.043] [Cited by in Crossref: 83] [Cited by in F6Publishing: 78] [Article Influence: 7.5] [Reference Citation Analysis]
345 Huang KW, Tam KW, Luo JC, Kuan YC. Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis. J Clin Gastroenterol 2017;51:539-47. [PMID: 28067752 DOI: 10.1097/MCG.0000000000000675] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
346 Lee HW, Yoo EJ, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy. Am J Gastroenterol. 2014;109:1241-1249. [PMID: 24957159 DOI: 10.1038/ajg.2014.157] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 10.0] [Reference Citation Analysis]
347 Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012;19:732-743. [PMID: 22967105 DOI: 10.1111/j.1365-2893.2012.01600.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 70] [Article Influence: 6.7] [Reference Citation Analysis]
348 Ma SW, Huang X, Li YY, Tang LB, Sun XF, Jiang XT, Zhang YX, Sun J, Liu ZH, Abbott WG, Dong YH, Naoumov NV, Hou JL. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B. J Hepatol. 2012;56:775-781. [PMID: 22173154 DOI: 10.1016/j.jhep.2011.10.020] [Cited by in Crossref: 67] [Cited by in F6Publishing: 73] [Article Influence: 6.1] [Reference Citation Analysis]
349 Tu HAT, Bos JH, Woerdenbag HJ, Visser ST, Wilschut JC, van Assen S, de Jong-van den Berg LT, Postma MJ. Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the Northern Netherlands between 2000 and 2006. Clinical Therapeutics 2010;32:133-44. [DOI: 10.1016/j.clinthera.2010.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
350 Zhang YM, Yang YD, Jia HY, Zeng LY, Yu W, Zhou N, Li LJ. HBsAg levels in HBeAg-positive chronic hepatitis B patients with different immune conditions. World J Gastroenterol 2014; 20(15): 4407-4413 [PMID: 24764680 DOI: 10.3748/wjg.v20.i15.4407] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
351 Zhong B, Huang MP, Yin GQ, Gao X. Effects of costimulation on intrahepatic immunopathogenesis in patients with chronic HBV infection. Inflamm Res 2014;63:217-29. [PMID: 24337678 DOI: 10.1007/s00011-013-0691-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
352 Miquel M, Núñez Ó, Trapero-marugán M, Díaz-sánchez A, Jiménez M, Arenas J, Canós AP. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Annals of Hepatology 2013;12:205-12. [DOI: 10.1016/s1665-2681(19)31358-4] [Cited by in Crossref: 24] [Article Influence: 2.7] [Reference Citation Analysis]
353 Beggel B, Neumann-Fraune M, Döring M, Lawyer G, Kaiser R, Verheyen J, Lengauer T. Genotyping hepatitis B virus dual infections using population-based sequence data. J Gen Virol 2012;93:1899-907. [PMID: 22694900 DOI: 10.1099/vir.0.043042-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
354 Feld J, Janssen HL, Abbas Z, Elewaut A, Ferenci P, Isakov V, Khan AG, Lim SG, Locarnini SA, Ono SK, Sollano J, Spearman CW, Yeh CT, Yuen MF, LeMair A. World Gastroenterology Organisation Global Guideline Hepatitis B: September 2015. J Clin Gastroenterol. 2016;50:691-703. [PMID: 27623512 DOI: 10.1097/mcg.0000000000000647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
355 McMahon BJ. Chronic hepatitis B virus infection. Med Clin North Am. 2014;98:39-54. [PMID: 24266913 DOI: 10.1016/j.mcna.2013.08.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.0] [Reference Citation Analysis]
356 Matsuura K, Tanaka Y, Kusakabe A, Hige S, Inoue J, Komatsu M, Kuramitsu T, Hirano K, Ohno T, Hasegawa I, Kobashi H, Hino K, Hiasa Y, Nomura H, Sugauchi F, Nojiri S, Joh T, Mizokami M. Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial: LAM-to-ETV switching treatment. Hepatology Research 2011;41:505-11. [DOI: 10.1111/j.1872-034x.2011.00807.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
357 Ha M, Zhang G, Diao S, Lin M, Sun L, She H, Kuan C, Shen L, Huang C, Shen W. A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. Arch Virol. 2012;157:285-290. [PMID: 22080196 DOI: 10.1007/s00705-011-1163-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
358 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
359 Ryu HJ, Lee JM, Ahn SH, Kim do Y, Lee MH, Han KH, Chon CY, Park JY. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol. 2010;82:1835-1842. [PMID: 20872709 DOI: 10.1002/jmv.21898] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
360 Hung CH, Hu TH, Lu SN, Lee CM, Chen CH, Kee KM, Wang JH, Tsai MC, Kuo YH, Chang KC, Chiu YC, Chen CH. Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation. Antimicrob Agents Chemother 2015;59:3168-73. [PMID: 25779569 DOI: 10.1128/AAC.00261-15] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
361 Kim BK, Park YN, Kim DY, Park JY, Chon CY, Han K, Ahn SH. Risk Assessment of Development of Hepatic Decompensation in Histologically Proven Hepatitis B Viral Cirrhosis Using Liver Stiffness Measurement. Digestion 2012;85:219-27. [DOI: 10.1159/000335430] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
362 Varghese J, Reddy MS, Cherian T, Vijaya S, Jayanthi V, Rela M. Anti-HBs response to hepatitis B immunoglobulin prophylaxis in liver transplant recipients. Indian J Gastroenterol 2014;33:226-30. [DOI: 10.1007/s12664-014-0457-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
363 Liang K, Hsu C, Chang M, Chen Y, Lai M, Yeh C. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. J Infect Dis 2016;213:966-74. [DOI: 10.1093/infdis/jiv547] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
364 Chiang H, Lee C, Hu T, Hung C, Wang J, Lu S, Lai H, Su W, Lin C, Peng C, Chen C. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. Liver Int 2018;38:1997-2005. [DOI: 10.1111/liv.13889] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
365 Kho-herman SGR, Chan HL. Stopping nucleos(t)ide analog treatment in chronic hepatitis B — Who and when? Liver Research 2017;1:135-9. [DOI: 10.1016/j.livres.2017.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
366 Lee KH, Aung MO, Lim SG. Are physicians following guidelines? A survey of Hepatitis B management strategies. Hepatol Int 2013;7:451-9. [DOI: 10.1007/s12072-012-9399-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
367 Zhao WF, Chen LY. Viral hepatitis B in children: clinical characteristics and antiviral treatment. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1624-1628 [DOI: 10.11569/wcjd.v19.i15.1624] [Reference Citation Analysis]
368 Ruan J, Li HJ, Sun DX. Reactivation of hepatitis B virus. Shijie Huaren Xiaohua Zazhi 2014; 22(7): 927-932 [DOI: 10.11569/wcjd.v22.i7.927] [Reference Citation Analysis]
369 Pan CJ, Wu HL, Kuo SF, Kao JH, Tseng TC, Liu CH, Chen PJ, Liu CJ, Chen DS. Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. Hepatol Int 2012;6:591-7. [PMID: 21769441 DOI: 10.1007/s12072-011-9299-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
370 Chu CM, Chen YC, Tai DI, Liaw YF. Level of hepatitis B virus DNA in inactive carriers with persistently normal levels of alanine aminotransferase. Clin Gastroenterol Hepatol. 2010;8:535-540. [PMID: 20304099 DOI: 10.1016/j.cgh.2010.03.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
371 Yao GB, Zhu M, Cui ZY, Wang BE, Yao JL, Zeng MD. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009;10:131-137. [PMID: 19426396 DOI: 10.1111/j.1751-2980.2009.00375.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
372 Wong VW, Wong GL, Tse CH, Yuen LK, Chan HY, Locarnini SA, Chan HL. Antiviral drug resistance testing in patients with chronic hepatitis B. Dig Dis Sci. 2012;57:221-231. [PMID: 21743991 DOI: 10.1007/s10620-011-1816-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
373 Ko SY, Oh HB, Park CW, Lee HC, Lee JE. Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing. Clin Microbiol Infect. 2012;18:E404-E411. [PMID: 22757653 DOI: 10.1111/j.1469-0691.2012.03951.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
374 Liu Z, Liu F, Wang L, Liu Y, Zhang M, Li T. Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study. Hepatol Res 2017;47:1000-7. [PMID: 27917568 DOI: 10.1111/hepr.12836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
375 Zhang H, Chao J, Zhu L, Song L, Li X, Liu P. Direct economic burden and influencing factors in patients with hepatitis B virus related diseases in Jiangsu, China. Asia Pac J Public Health 2015;27:41S-8S. [PMID: 25416293 DOI: 10.1177/1010539514560057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
376 Dembek C, Protzer U, Roggendorf M. Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination. Curr Opin Virol 2018;30:58-67. [PMID: 29751272 DOI: 10.1016/j.coviro.2018.04.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
377 Xu SH, Li Q, Hu YP, Ying L. Development of a model based on biochemical, real‑time tissue elastography and ultrasound data for the staging of liver fibrosis and cirrhosis in patients with chronic hepatitis B. Mol Med Rep 2016;14:3609-19. [PMID: 27573619 DOI: 10.3892/mmr.2016.5682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
378 Stroffolini T, Spadaro A, Di Marco V, Scifo G, Russello M, Montalto G, Bertino G, Surace L, Caroleo B, Foti G, Portelli V, Madonia S, Sapienza M, Cosco L, Frugiuele P, Galdieri A, Brandolino N, Siciliano R, Bruno S, Almasio PL; Gr.E.Ca.S. Hospitals' Collaborating Group. Current practice of chronic hepatitis B treatment in Southern Italy. Eur J Intern Med 2012;23:e124-7. [PMID: 22726382 DOI: 10.1016/j.ejim.2012.03.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
379 Zhou YL, Duan ZJ. Viral versus alcoholic cirrhosis: clinical characteristics, prophylaxis and treatment. Shijie Huaren Xiaohua Zazhi 2010; 18(31): 3313-3319 [DOI: 10.11569/wcjd.v18.i31.3313] [Reference Citation Analysis]
380 Méndez-Navarro J, Corey KE, Zheng H, Barlow LL, Jang JY, Lin W, Zhao H, Shao RX, McAfee SL, Chung RT. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int 2011;31:330-9. [PMID: 20738779 DOI: 10.1111/j.1478-3231.2010.02332.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
381 Wong VW, Sung JJ. Diagnosis and personalized management of hepatitis B including significance of genotypes: . Current Opinion in Infectious Diseases 2012;25:570-7. [DOI: 10.1097/qco.0b013e328357f2f8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
382 Chi H, Hansen BE, Yim C, Arends P, Abu-Amara M, van der Eijk AA, Feld JJ, de Knegt RJ, Wong DK, Janssen HL. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2015;41:867-876. [PMID: 25752878 DOI: 10.1111/apt.13150] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 9.7] [Reference Citation Analysis]
383 Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, Hige S, Yatsuhashi H, Nagaoka S, Chayama K, Tsuge M, Yokosuka O, Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. Hepatol Res 2012;42:139-49. [PMID: 22103237 DOI: 10.1111/j.1872-034X.2011.00910.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
384 Li L, Liu W, Chen YH, Fan CL, Dong PL, Wei FL, Li B, Chen DX, Ding HG. Antiviral drug resistance increases hepatocellular carcinoma: A prospective decompensated cirrhosis cohort study. World J Gastroenterol 2013; 19(45): 8373-8381 [PMID: 24363530 DOI: 10.3748/wjg.v19.i45.8373] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
385 Chan HC, Wong VW, Wong GL, Tang W, Wu JC, Ng SC. Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region. BMC Gastroenterol. 2016;16:100. [PMID: 27549153 DOI: 10.1186/s12876-016-0516-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
386 Shin SR, Koh KC, Gwak GY, Choi MS, Lee JH, Paik SW, Yoo BC. A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B. J Gut Liver. 2010;4:530-536. [PMID: 21253304 DOI: 10.5009/gnl.2010.4.4.530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
387 Lee HW, Lee SH, Lee MG, Ahn SH, Chang HY, Han KH. The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine. J Med Virol 2016;88:820-7. [PMID: 26400223 DOI: 10.1002/jmv.24393] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
388 Zeng X, Xu C, He D, Li M, Zhang H, Wu Q, Xiang D, Wang Y. Performance of several simple, noninvasive models for assessing significant liver fibrosis in patients with chronic hepatitis B. Croat Med J. 2015;56:272-279. [PMID: 26088852 DOI: 10.3325/cmj.2015.56.272] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
389 Chevaliez S. Is HBsAg quantification ready, for prime time? Clin Res Hepatol Gastroenterol. 2013;37:559-563. [PMID: 23932705 DOI: 10.1016/j.clinre.2013.07.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
390 Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs. 2009;69:2167-2177. [PMID: 19852523 DOI: 10.2165/11319850-000000000-00000] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
391 Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother. 2011;12:2025-2040. [PMID: 21682661 DOI: 10.1517/14656566.2011.590474] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
392 Liu C, Ye J, Jia H, Zhang M, Han H, Chen F, Chen C. Entecavir and lamivudine therapy for severe acute chronic hepatitis B. Exp Ther Med. 2013;5:545-548. [PMID: 23403957 DOI: 10.3892/etm.2012.850] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
393 Deng M, Zhou X, Gao S, Yang SG, Wang B, Chen HZ, Ruan B. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J 2012;9:185. [PMID: 22947333 DOI: 10.1186/1743-422X-9-185] [Cited by in Crossref: 54] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
394 Dény P, Zoulim F. Hepatitis B virus: from diagnosis to treatment. Pathol Biol (Paris). 2010;58:245-253. [PMID: 20580167 DOI: 10.1016/j.patbio.2010.05.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
395 Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong C, Wong J, Lee K, Lai PB, Chan HL. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma: Meta-analysis: anti-viral therapy and HCC recurrence. Alimentary Pharmacology & Therapeutics 2011;33:1104-12. [DOI: 10.1111/j.1365-2036.2011.04634.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 110] [Article Influence: 10.5] [Reference Citation Analysis]
396 Papatheodoridis GV. Hepatitis B virus treatment: Which patients can have treatment deferred? Clin Liver Dis (Hoboken). 2013;2:15-17. [PMID: 30992813 DOI: 10.1002/cld.160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
397 Wei L, Hu S, Hou J, Liu G, Ren H, Duan Z, Xie Q, Fang X, Jia J. A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China. Value Health Reg Issues 2013;2:48-56. [PMID: 29702852 DOI: 10.1016/j.vhri.2013.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
398 Kim MN, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Song KJ, Park YN, Han KH. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 2015;61:1851-1859. [PMID: 25643638 DOI: 10.1002/hep.27735] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 13.4] [Reference Citation Analysis]
399 Tian Y, Sun LM, Liu XQ, Li B, Wang Q, Dong JX. Anti-HBV active flavone glucosides from Euphorbia humifusa Willd. Fitoterapia 2010;81:799-802. [PMID: 20450964 DOI: 10.1016/j.fitote.2010.04.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
400 Juday T, Tang H, Harris M, Powers AZ, Kim E, Hanna GJ. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment. J Gen Intern Med 2011;26:239-44. [PMID: 20978862 DOI: 10.1007/s11606-010-1549-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
401 Einollahi B. Therapy for HBV Infection in Hemodialysis Patients: Is it Possible? Hepat Mon 2012;12:153-7. [PMID: 22550522 DOI: 10.5812/hepatmon.834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
402 Mamun-Al-Mahtab, Akbar SMF, Uddin H, Khan SI, Rahman S. Early termination of immune tolerance state of hepatitis B virus infection explains liver damage. World J Hepatol 2014; 6(8): 621-625 [PMID: 25232455 DOI: 10.4254/wjh.v6.i8.621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
403 Buster EH, Hansen BE, Lau GK, Piratvisuth T, Zeuzem S, Steyerberg EW, Janssen HL. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137:2002-2009. [PMID: 19737568 DOI: 10.1053/j.gastro.2009.08.061] [Cited by in Crossref: 265] [Cited by in F6Publishing: 251] [Article Influence: 20.4] [Reference Citation Analysis]
404 Jeon HJ, Jung SW, Park NH, Yang Y, Noh JH, Ahn JS, Kim HR, Lee JH, Shin JW. Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. Clin Mol Hepatol 2017;23:230-8. [PMID: 28669175 DOI: 10.3350/cmh.2017.0003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
405 Park H, Kim SU, Kim D, Kim do Y, Ahn SH, Han KH, Chon CY, Park JY. Optimal time for restoring the reliability of liver stiffness measurement in patients with chronic hepatitis B experiencing acute exacerbation. J Clin Gastroenterol. 2012;46:602-607. [PMID: 22772739 DOI: 10.1097/mcg.0b013e3182582a31] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
406 Sohn HR, Min BY, Song JC, Seong MH, Lee SS, Jang ES, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW. Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis. 2014;14:439. [PMID: 25125320 DOI: 10.1186/1471-2334-14-439] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
407 Kim DS, Park SY, Kim BK, Park JY, Kim DY, Han KH, Lee YR, Tak WY, Kweon YO, Jung I, Han M, Kim EH, Ahn SH, Kim SU. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. J Korean Med Sci 2021;36:e105. [PMID: 33904261 DOI: 10.3346/jkms.2021.36.e105] [Reference Citation Analysis]
408 Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist. 2011;4:55-64. [PMID: 21694909 DOI: 10.2147/idr.s4188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
409 Pan XC, Ren JS. Antiviral therapy in patients with concomitant chronic hepatitis B and autoimmune diseases. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1629-1633 [DOI: 10.11569/wcjd.v19.i15.1629] [Reference Citation Analysis]
410 Harkisoen S, Arends JE, van den Hoek JA, Whelan J, van Erpecum KJ, Boland GJ, Hoepelman AI. Historic and current hepatitis B viral DNA and quantitative HBsAg level are not associated with cirrhosis in non-Asian women with chronic hepatitis B. Int J Infect Dis 2014;29:133-8. [PMID: 25449247 DOI: 10.1016/j.ijid.2014.08.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
411 Yang J, Zhang Y, Luo L, Meng R, Yu C. Global Mortality Burden of Cirrhosis and Liver Cancer Attributable to Injection Drug Use, 1990-2016: An Age-Period-Cohort and Spatial Autocorrelation Analysis. Int J Environ Res Public Health 2018;15:E170. [PMID: 29361804 DOI: 10.3390/ijerph15010170] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
412 Ma L, Song J, Shi Y, Wang C, Chen B, Xie D, Jia X. Anti-hepatitis B virus activity of chickweed [Stellaria media (L.) Vill.] extracts in HepG2.2.15 cells. Molecules 2012;17:8633-46. [PMID: 22810196 DOI: 10.3390/molecules17078633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
413 Hsiang JC, Wong GL, Tse YK, Wong VW, Yip TC, Chan HL. Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. J Hepatol. 2015;63:1190-1197. [PMID: 26208777 DOI: 10.1016/j.jhep.2015.07.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
414 Yin JW, Ping Huang M, Zhong B. Intrahepatic Toll-Like Receptor 3 in Chronic HBV Infection Subjects: Asymptomatic Carriers, Active Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma. Hepat Mon 2016;16:e34432. [PMID: 27630720 DOI: 10.5812/hepatmon.34432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
415 Liaw YF, Lau GK, Kao JH, Gane E. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55:2727-2734. [PMID: 20238245 DOI: 10.1007/s10620-010-1179-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis]
416 Yang Y, Ma L, Wang C, Kong D, Wang Y, Mei C. Effectiveness of sulodexide might be associated with inhibition of complement system in hepatitis B virus-associated membranous nephropathy: An inspiration from a pilot trial. Eur J Intern Med 2016;32:96-104. [PMID: 27160380 DOI: 10.1016/j.ejim.2016.04.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
417 Ringelhan M, O'Connor T, Protzer U, Heikenwalder M. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol. 2015;235:355-367. [PMID: 25196558 DOI: 10.1002/path.4434] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 11.1] [Reference Citation Analysis]
418 Shindo M, Chayama K, Mochida S, Toyota J, Tomita E, Kumada H, Yokosuka O, Sata M, Hayashi N, Suzuki K, Okanoue T, Tsubouchi H, Ishikawa H, Seriu T, Omata M. Antiviral activity, dose-response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial. Hepatol Int 2009;3:445-52. [PMID: 19669249 DOI: 10.1007/s12072-009-9135-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
419 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol 2012; 18(48): 7149-7157 [PMID: 23326119 DOI: 10.3748/wjg.v18.i48.7149] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
420 Jin YJ, Kim KM, Yoo DJ, Shim JH, Lee HC, Chung YH, Lee YS, Suh DJ. Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients. Virol J. 2012;9:239. [PMID: 23078793 DOI: 10.1186/1743-422x-9-239] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
421 Yu SJ, Kim YJ. Hepatitis B viral load affects prognosis of hepatocellular carcinoma. World J Gastroenterol 2014; 20(34): 12039-12044 [PMID: 25232241 DOI: 10.3748/wjg.v20.i34.12039] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
422 Lin C, Kao J. The clinical implications of hepatitis B virus genotype: Recent advances: HBV genotype and clinical outcomes. Journal of Gastroenterology and Hepatology 2011;26:123-30. [DOI: 10.1111/j.1440-1746.2010.06541.x] [Cited by in Crossref: 222] [Cited by in F6Publishing: 222] [Article Influence: 20.2] [Reference Citation Analysis]
423 Resnick E, Shteingart S, Melamud B, Bdolah-Abram T, Zalut T, Reuben A, Lurie Y. Enzyme pattern of biliary colic: A counterintuitive picture. World J Hepatol 2016; 8(36): 1629-1636 [PMID: 28083086 DOI: 10.4254/wjh.v8.i36.1629] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
424 Liaw Y, Chu C. Hepatitis B virus infection. The Lancet 2009;373:582-92. [DOI: 10.1016/s0140-6736(09)60207-5] [Cited by in Crossref: 833] [Cited by in F6Publishing: 366] [Article Influence: 64.1] [Reference Citation Analysis]
425 Kobashi H, Miyake Y, Ikeda F, Yasunaka T, Nishino K, Moriya A, Kubota J, Nakamura S, Takaki A, Nouso K, Yamada G, Yamamoto K. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol Res 2011;41:405-16. [PMID: 21435126 DOI: 10.1111/j.1872-034X.2011.00785.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
426 Yoo HJ, Jung KJ, Kim M, Kim M, Kang M, Jee SH, Choi Y, Lee JH. Liver Cirrhosis Patients Who Had Normal Liver Function Before Liver Cirrhosis Development Have the Altered Metabolic Profiles Before the Disease Occurrence Compared to Healthy Controls. Front Physiol 2019;10:1421. [PMID: 31803070 DOI: 10.3389/fphys.2019.01421] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
427 Seto WK, Wong DK, Fung J, Ip PP, Yuen JC, Hung IF, Lai CL, Yuen MF. High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B. PLoS One. 2012;7:e43087. [PMID: 22916211 DOI: 10.1371/journal.pone.0043087] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
428 Jang JW. Hepatitis B virus reactivation in patients with hepatocellular carcinoma undergoing anti-cancer therapy. World J Gastroenterol 2014; 20(24): 7675-7685 [PMID: 24976705 DOI: 10.3748/wjg.v20.i24.7675] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
429 Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 695] [Cited by in F6Publishing: 660] [Article Influence: 69.5] [Reference Citation Analysis]
430 Xie SB, Ma C, Lin CS, Zhang Y, Zhu JY, Ke WM. Collagen proportionate area of liver tissue determined by digital image analysis in patients with HBV-related decompensated cirrhosis. Hepatobiliary Pancreat Dis Int. 2011;10:497-501. [PMID: 21947723 DOI: 10.1016/s1499-3872(11)60084-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
431 Degenhardt L, Charlson F, Stanaway J, Larney S, Alexander LT, Hickman M, Cowie B, Hall WD, Strang J, Whiteford H. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016;16:1385-1398. [PMID: 27665254 DOI: 10.1016/s1473-3099(16)30325-5] [Cited by in Crossref: 135] [Cited by in F6Publishing: 72] [Article Influence: 22.5] [Reference Citation Analysis]
432 Wang H, Thorling CA, Liang X, Bridle KR, Grice JE, Zhu Y, Crawford DHG, Xu ZP, Liu X, Roberts MS. Diagnostic imaging and therapeutic application of nanoparticles targeting the liver. J Mater Chem B 2015;3:939-58. [PMID: 32261972 DOI: 10.1039/c4tb01611d] [Cited by in Crossref: 67] [Cited by in F6Publishing: 12] [Article Influence: 9.6] [Reference Citation Analysis]
433 Zheng XY, Wei RB, Tang L, Li P, Zheng XD. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol 2012; 18(8): 821-832 [PMID: 22371643 DOI: 10.3748/wjg.v18.i8.821] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
434 Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology. 2012;55:68-76. [PMID: 21858846 DOI: 10.1002/hep.24615] [Cited by in Crossref: 96] [Cited by in F6Publishing: 96] [Article Influence: 9.6] [Reference Citation Analysis]
435 Batirel A, Guclu E, Arslan F, Kocak F, Karabay O, Ozer S, Turanli M, Mert A. Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study. Int J Infect Dis 2014;28:153-9. [PMID: 25286184 DOI: 10.1016/j.ijid.2014.09.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
436 Bessone F. Re-appraisal of old and new diagnostic tools in the current management of chronic hepatitis B. Liver Int. 2014;34:991-1000. [PMID: 25098191 DOI: 10.1111/liv.12499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
437 Chen SS, Yu KK, Ling QX, Huang C, Li N, Zheng JM, Bao SX, Cheng Q, Zhu MQ, Chen MQ. Factors associated with significant liver necroinflammation in chronic hepatitis B patients with cirrhosis. Sci Rep 2016;6:33093. [PMID: 27615602 DOI: 10.1038/srep33093] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
438 Li CZ, Cheng LF, Li QS, Wang ZQ, Yan JH. Antiviral therapy delays esophageal variceal bleeding in hepatitis B virus-related cirrhosis. World J Gastroenterol 2013; 19(40): 6849-6856 [PMID: 24187460 DOI: 10.3748/wjg.v19.i40.6849] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
439 Li X, Xu H, Gao P. Red Blood Cell Distribution Width-to-Platelet Ratio and Other Laboratory Indices Associated with Severity of Histological Hepatic Fibrosis in Patients with Autoimmune Hepatitis: A Retrospective Study at a Single Center. Med Sci Monit 2020;26:e927946. [PMID: 33180750 DOI: 10.12659/MSM.927946] [Reference Citation Analysis]
440 Juniastuti, Utsumi T, Aksono EB, Yano Y, Soetjipto, Hayashi Y, Hotta H, Rantam FA, Kusumobroto HO, Lusida MI. Predominance of precore mutations and clinical significance of basal core promoter mutations in chronic hepatitis B virus infection in Indonesia. Biomed Rep 2013;1:522-8. [PMID: 24648979 DOI: 10.3892/br.2013.106] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
441 Warner BG, Tsai P, Rodrigo AG, ‘Ofanoa M, Gane EJ, Munn SR, Abbott WGH. Evidence for reduced selection pressure on the hepatitis B virus core gene in hepatitis B e antigen-negative chronic hepatitis B. Journal of General Virology 2011;92:1800-8. [DOI: 10.1099/vir.0.030478-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
442 Lim YS. Management of Antiviral Resistance in Chronic Hepatitis B. Gut Liver 2017;11:189-95. [PMID: 28183162 DOI: 10.5009/gnl15562] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
443 Han J, Pan X, Gao Y, Weil L. Inhibition of hepatitis B virus replication by the internal fragment of hepatitis B core protein. Virus Res 2010;150:129-34. [PMID: 20303370 DOI: 10.1016/j.virusres.2010.03.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
444 Lee S, Park JY, Kim do Y, Kim BK, Kim SU, Song K, Ku HJ, Han KH, Ahn SH. Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. J Med Virol. 2016;88:1027-1034. [PMID: 26538234 DOI: 10.1002/jmv.24427] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
445 Su Z, Li Y, Liao Y, Cai B, Chen J, Zhang J, Li L, Ying B, Tao C, Wang L. Association of the gene polymorphisms in sodium taurocholate cotransporting polypeptide with the outcomes of hepatitis B infection in Chinese Han population. Infect Genet Evol 2014;27:77-82. [PMID: 25010264 DOI: 10.1016/j.meegid.2014.07.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
446 Buchanan C, Tran TT. Management of chronic hepatitis B in pregnancy. Clin Liver Dis. 2010;14:495-504. [PMID: 20638027 DOI: 10.1016/j.cld.2010.05.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
447 Ataei B, Khodadoostan M, Pouria B, Adibi P. Tenofovir in treatment of Iranian patients with chronic hepatitis B virus infection: An open-label case series. J Res Pharm Pract 2016;5:166-70. [PMID: 27512706 DOI: 10.4103/2279-042X.185714] [Reference Citation Analysis]
448 Kim BU, Goo JC, Park BC, Kim SO, Hong SP, Jeong JI, Chae HB, Park SM, Youn SJ. Genotypic resistance to entecavir in chronic hepatitis B patients. Korean J Hepatol 2010;16:147. [DOI: 10.3350/kjhep.2010.16.2.147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
449 Hu D, Bower W, Ward J. Viral Hepatitis. Atlas of Sexually Transmitted Diseases and AIDS. Elsevier; 2010. pp. 203-29. [DOI: 10.1016/b978-0-7020-4060-3.00012-0] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
450 Yoon EL, Yim HJ, Lee HJ, Lee YS, Kim JH, Jung ES, Kim JH, Seo YS, Yeon JE, Lee HS. Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data. J Clin Gastroenterol. 2011;45:893-899. [PMID: 21617542 DOI: 10.1097/mcg.0b013e31821f8bdf] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
451 Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, Levy M, Locarnini SA. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia. J Hepatol. 2010;52:508-513. [PMID: 20206400 DOI: 10.1016/j.jhep.2010.01.007] [Cited by in Crossref: 243] [Cited by in F6Publishing: 232] [Article Influence: 20.3] [Reference Citation Analysis]
452 Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int. 2019;13:665-673. [PMID: 31559604 DOI: 10.1007/s12072-019-09989-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
453 Suh DJ, Um SH, Herrmann E, Kim JH, Lee YS, Lee HJ, Lee MS, Lee YJ, Bao W, Lopez P. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. Antimicrob Agents Chemother. 2010;54:1242-1247. [PMID: 20028815 DOI: 10.1128/aac.01163-09] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
454 Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL, Schluep T. Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. Antiviral Res 2015;121:47-58. [PMID: 26092643 DOI: 10.1016/j.antiviral.2015.06.008] [Cited by in Crossref: 151] [Cited by in F6Publishing: 136] [Article Influence: 21.6] [Reference Citation Analysis]
455 Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X, Sun J. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi J Gastroenterol 2015;21:245-53. [PMID: 26228369 DOI: 10.4103/1319-3767.161645] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
456 Wang LY, Fan YC, Zhao J, Ji XF, Wang K. Increased BATF expression is associated with the severity of liver damage in patients with chronic hepatitis B. Clin Exp Med 2018;18:263-72. [PMID: 29164410 DOI: 10.1007/s10238-017-0480-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
457 Razlan H, Marzuki NM, Tai ML, Shamsul AS, Ong TZ, Mahadeva S. Diagnostic value of the C methacetin breath test in various stages of chronic liver disease. Gastroenterol Res Pract. 2011;2011:235796. [PMID: 21687605 DOI: 10.1155/2011/235796] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
458 Lee JH, Cho Y, Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yu SJ, Yoon JH. Prior exposure to lamivudine increases entecavir resistance risk in chronic hepatitis B Patients without detectable lamivudine resistance. Antimicrob Agents Chemother. 2014;58:1730-1737. [PMID: 24395227 DOI: 10.1128/aac.02483-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
459 Fan CX, Li XF, Zhan YF, Zheng QY, Feng Q, Shi XY, Li YJ, Tan HB. Efficacy and safety of interferon α-2b as an add-on therapy to long-term oral nucleotide analogue therapy in hepatitis B e antigen-negative patients. Shijie Huaren Xiaohua Zazhi 2017; 25(11): 983-988 [DOI: 10.11569/wcjd.v25.i11.983] [Reference Citation Analysis]
460 Lim TH, Gane E, Moyes C, Borman B, Cunningham C. Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Māori: results from a 28-year follow-up study. Gut 2015;64:966-72. [PMID: 25006011 DOI: 10.1136/gutjnl-2013-306247] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
461 Yang HC, Chen CL, Shen YC, Peng CY, Liu CJ, Tseng TC, Su TH, Chuang WL, Yu ML, Dai CY. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. Hepatology. 2013;57:934-943. [PMID: 23112104 DOI: 10.1002/hep.26121] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
462 Lim SG, Mohammed R, Yuen M, Kao J. Prevention of hepatocellular carcinoma in hepatitis B virus infection. Journal of Gastroenterology and Hepatology 2009;24:1352-7. [DOI: 10.1111/j.1440-1746.2009.05985.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
463 Holness G, Carriero DC, Dieterich DT. Hepatitis B therapies and antiviral resistance detection and management. Expert Review of Gastroenterology & Hepatology 2014;3:693-9. [DOI: 10.1586/egh.09.64] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
464 Lee IC, Lin CH, Huang YH, Huo TI, Su CW, Hou MC, Huang HC, Lee KC, Chan CC, Lin MW. IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B. PLoS One. 2013;8:e58071. [PMID: 23469142 DOI: 10.1371/journal.pone.0058071] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
465 Zheng B, Yang Y, Han Q, Yin C, Pan Z, Zhang J. STAT3 directly regulates NKp46 transcription in NK cells of HBeAg-negative CHB patients. J Leukoc Biol 2019;106:987-96. [PMID: 31132315 DOI: 10.1002/JLB.2A1118-421R] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
466 Sarkar M, Shvachko VA, Ready JB, Pauly MP, Terrault NA, Peters MG, Manos MM. Characteristics and management of patients with chronic hepatitis B in an integrated care setting. Dig Dis Sci. 2014;59:2100-2108. [PMID: 24728968 DOI: 10.1007/s10620-014-3142-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
467 Ide T, Sata M, Chayama K, Shindo M, Toyota J, Mochida S, Tomita E, Kumada H, Yamada G, Yatsuhashi H, Hayashi N, Ishikawa H, Seriu T, Omata M. Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy. Hepatol Int 2010;4:594-600. [PMID: 21063482 DOI: 10.1007/s12072-010-9185-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
468 Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Group SGHOBOARS. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 2015; 21(38): 10874-10882 [PMID: 26478678 DOI: 10.3748/wjg.v21.i38.10874] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
469 Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B: Lamivudine resistance. Hepatol Int. 2008;2:440-456. [PMID: 19669319 DOI: 10.1007/s12072-008-9105] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
470 Chotiyaputta W, Degertekin B, McKenna BJ, Samala N, Fontana RJ, Lok AS. Characteristics of chronic hepatitis B patients who underwent liver biopsies. J Viral Hepat 2011;18:792-803. [PMID: 20726947 DOI: 10.1111/j.1365-2893.2010.01364.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
471 Terrault N. Management strategies for hepatitis B-infected patients undergoing immunomodulatory therapy: Is lamivudine enough? Clinical Liver Disease. 2015;5:43-46. [PMID: 31040947 DOI: 10.1002/cld.447] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
472 Ha NB, Trinh HN, Rosenblatt L, Nghiem D, Nguyen MH. Treatment Outcomes With First-line Therapies With Entecavir and Tenofovir in Treatment-Naive Chronic Hepatitis B Patients in a Routine Clinical Practice. Journal of Clinical Gastroenterology 2016;50:169-74. [DOI: 10.1097/mcg.0000000000000345] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
473 Gao S, Li XY, Fan YC, Sun FK, Han LY, Li F, Ji XF, Wang K. A noninvasive model to predict liver histology in HBeAg-positive chronic hepatitis B with alanine aminotransferase ≤ 2upper limit of normal. J Gastroenterol Hepatol 2017;32:215-20. [PMID: 27207016 DOI: 10.1111/jgh.13452] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
474 Du W, Zhen J, Zheng Z, Ma S, Chen S. Expression of AIM2 is high and correlated with inflammation in hepatitis B virus associated glomerulonephritis. J Inflamm (Lond). 2013;10:37. [PMID: 24325587 DOI: 10.1186/1476-9255-10-37] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
475 Lee M, Keeffe EB. Hepatitis B: modern end points of treatment and the specter of viral resistance. Gastroenterol Clin North Am. 2011;40:495-505. [PMID: 21893270 DOI: 10.1016/j.gtc.2011.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
476 Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol 2014; 20(23): 7312-7324 [PMID: 24966602 DOI: 10.3748/wjg.v20.i23.7312] [Cited by in CrossRef: 202] [Cited by in F6Publishing: 178] [Article Influence: 25.3] [Reference Citation Analysis]
477 Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, Zhong S, Johnson PJ. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:553-561. [PMID: 12794717 DOI: 10.1002/jmv.10430] [Cited by in Crossref: 149] [Cited by in F6Publishing: 138] [Article Influence: 7.8] [Reference Citation Analysis]
478 Xu Y, Zhang YG, Wang X, Qi WQ, Qin SY, Liu ZH, Jiao J, Wang JB. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol 2015; 21(25): 7869-7876 [PMID: 26167087 DOI: 10.3748/wjg.v21.i25.7869] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
479 Zhang C, Ke W, Liu L, Gao Y, Yao Z, Ye X, Zhou S, Yang Y. Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients. Drug Des Devel Ther 2016;10:897-910. [PMID: 27041994 DOI: 10.2147/DDDT.S98200] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
480 Janssen HL, Buster EH. Comments on the EASL practice guidelines for the management of chronic hepatitis B: Controversies in interferon-based therapy. Journal of Hepatology 2009;51:224-6. [DOI: 10.1016/j.jhep.2009.02.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
481 Chen T, Wang J, Qiu H, Yu Q, Yan T, Qi C, Cao F, Tian Z, Guo D, Yao N, Yang Y, He Y, Zhao Y, Liu J. Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-): Epidemiological data from Shaanxi, China. Medicine (Baltimore) 2018;97:e11406. [PMID: 29979437 DOI: 10.1097/MD.0000000000011406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
482 Keating GM. Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B. Drugs 2009;69:2633-60. [PMID: 19943712 DOI: 10.2165/11203660-000000000-00000] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
483 Buti M, Oyagüez I, Lozano V, Casado MA. Cost effectiveness of first-line oral antiviral therapies for chronic hepatitis B: a systematic review. Pharmacoeconomics. 2013;31:63-75. [PMID: 23329593 DOI: 10.1007/s40273-012-0009-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
484 Choi MS, Yoo BC. Management of chronic hepatitis B with nucleoside or nucleotide analogues: a review of current guidelines. Gut Liver 2010;4:15-24. [PMID: 20479908 DOI: 10.5009/gnl.2010.4.1.15] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
485 Liu C, Wang YM, Fan K. Epidemiological and clinical features of hepatitis B virus related liver failure in China. World J Gastroenterol 2011; 17(25): 3054-3059 [PMID: 21799653 DOI: 10.3748/wjg.v17.i25.3054] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
486 Aung MN, Leowattana W, Tangpukdee N, Kittitrakul C. Nucleos(t)ide analogues treatment outcome in genotype B and C chronic hepatitis B. N Am J Med Sci 2010;2:365-70. [PMID: 22737674 DOI: 10.4297/najms.2010.2365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
487 Pollack HJ, Kwon SC, Wang SH, Wyatt LC, Trinh-Shevrin C. Chronic hepatitis B and liver cancer risks among Asian immigrants in New York City: Results from a large, community-based screening, evaluation, and treatment program. Cancer Epidemiol Biomarkers Prev. 2014;23:2229-2239. [PMID: 25368398 DOI: 10.1158/1055-9965.epi-14-0491] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
488 Amarapurkar D, Han K, Chan HL, Ueno Y; The Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. Journal of Gastroenterology and Hepatology 2009;24:955-61. [DOI: 10.1111/j.1440-1746.2009.05805.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
489 Dienstag JL. Peginterferon therapy for HBeAg-negative chronic hepatitis B: less than meets the eye. Am J Gastroenterol 2010;105:1770-2. [PMID: 20686463 DOI: 10.1038/ajg.2010.187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
490 Brown A, Goodman Z. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs. Expert Review of Gastroenterology & Hepatology 2014;6:187-98. [DOI: 10.1586/egh.12.4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
491 Yao GB, Ren H, Xu DZ, Zhou XQ, Jia JD, Wang YM, Chen CW. Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients. J Viral Hepat 2010;17 Suppl 1:51-8. [PMID: 20586934 DOI: 10.1111/j.1365-2893.2010.01271.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
492 Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH Guidelines for the Management of Hepatitis B Virus Infection. Hepatol Res. 2014;44 Suppl S1:1-58. [PMID: 24397839 DOI: 10.1111/hepr.12269] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 12.9] [Reference Citation Analysis]
493 Ratnam D, Dev A, Nguyen T, Sundararajan V, Harley H, Cheng W, Lee A, Rusli F, Chen R, Bell S, Pianko S, Sievert W. Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: a multicenter clinical experience. J Gastroenterol Hepatol 2012;27:1447-53. [PMID: 22168789 DOI: 10.1111/j.1440-1746.2011.07051.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
494 Yeh ML, Huang CF, Hsieh MY, Huang JF, Dai CY, Yu ML, Chuang WL. Comparison of the Abbott RealTime HBV assay with the Roche Cobas AmpliPrep/Cobas TaqMan HBV assay for HBV DNA detection and quantification. J Clin Virol. 2014;60:206-214. [PMID: 24809730 DOI: 10.1016/j.jcv.2014.04.008] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
495 Jafri SR, Lok AS. Antiviral Therapy for Chronic Hepatitis B. Clinics in Liver Disease 2010;14:425-38. [DOI: 10.1016/j.cld.2010.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
496 Yu LH, Li N, Cheng SQ. The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. Int J Hepatol. 2011;2011:416459. [PMID: 21994855 DOI: 10.4061/2011/416459] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
497 Seto WK, Lee CF, Lai CL, Ip PP, Fong DY, Fung J, Wong DK, Yuen MF. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One. 2011;6:e23077. [PMID: 21853071 DOI: 10.1371/journal.pone.0023077] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
498 Kumar M, Chauhan R, Gupta N, Hissar S, Sakhuja P, Sarin SK. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients. Gastroenterology. 2009;136:1272-1280. [PMID: 19208347 DOI: 10.1053/j.gastro.2009.01.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
499 Kwak MS, Cho EJ, Jang ES, Lee JH, Yu SJ, Kim YJ, Yoon JH, Lee HS. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients. Digestion. 2011;84 Suppl 1:23-28. [PMID: 22156482 DOI: 10.1159/000333211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
500 Lu X, Qin B, Ma Q, Yang C, Gong XY, Chen LM. Differential expression of ISG20 in chronic hepatitis B patients and relation to interferon-alpha therapy response. J Med Virol 2013;85:1506-12. [PMID: 23794439 DOI: 10.1002/jmv.23610] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
501 Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, Lu SN, Chien RN, Lee CM. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. J Hepatol. 2014;60:1127-1134. [PMID: 24583247 DOI: 10.1016/j.jhep.2014.02.013] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
502 Kadri H, Blank S, Wang Q, Kim K, Fiel M, Luan W, Hiotis S. Outcomes following liver resection and clinical pathologic characteristics of hepatocellular carcinoma occurring in patients with chronic hepatitis B and minimally fibrotic liver. European Journal of Surgical Oncology (EJSO) 2013;39:1371-6. [DOI: 10.1016/j.ejso.2013.09.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
503 Shukla A, Gupte A, Gupte P, Modi T, Joshi A, Chaturvedi R, Thakkar H, Bhatia S. Chronic HBV-infected subjects older than 35 years with persistently normal ALT and ultrasound, despite high viral load do not have significant fibrosis. Indian J Gastroenterol. 2015;34:341-342. [PMID: 25990094 DOI: 10.1007/s12664-015-0557-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
504 Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537-1547. [PMID: 23389810 DOI: 10.1002/hep.26301] [Cited by in Crossref: 295] [Cited by in F6Publishing: 283] [Article Influence: 32.8] [Reference Citation Analysis]
505 Guirgis BS, Abbas RO, Azzazy HM. Hepatitis B virus genotyping: current methods and clinical implications. International Journal of Infectious Diseases 2010;14:e941-53. [DOI: 10.1016/j.ijid.2010.03.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
506 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
507 Kim S, Lee Y, Bang SM, Bak H, Yim SY, Lee YS, Yoo YJ, Jung YK, Kim JH, Seo YS, Yim HJ, Um SH, Byun KS, Yeon JE. Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients. J Clin Med 2021;10:1840. [PMID: 33922708 DOI: 10.3390/jcm10091840] [Reference Citation Analysis]
508 Zhao J, Zhai F, Cheng J, He Q, Luo J, Yang X, Shao J, Xing H. Evaluating the Significance of Viscoelasticity in Diagnosing Early-Stage Liver Fibrosis with Transient Elastography. PLoS One. 2017;12:e0170073. [PMID: 28107385 DOI: 10.1371/journal.pone.0170073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
509 Watanabe K, Takase K, Ohno S, Ideguchi H, Nozaki A, Ishigatsubo Y. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Modern Rheumatology 2014;22:470-3. [DOI: 10.3109/s10165-011-0521-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
510 Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat 2012;19:377-86. [PMID: 22571899 DOI: 10.1111/j.1365-2893.2012.01602.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 88] [Article Influence: 8.4] [Reference Citation Analysis]
511 Chainuvati S, Cheng J, Hou JL, Hsu CW, Jia JD, Komolmit P, Kwon SY, Lee CH, Li H, Li Y. Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand. Hepatol Int. 2009;3:453-460. [PMID: 19669246 DOI: 10.1007/s12072-009-9139-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
512 Sereno L, Mesquita F, Kato M, Jacka D, Nguyen TT, Nguyen TN. Epidemiology, responses, and way forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam. J Int Assoc Physicians AIDS Care (Chic). 2012;11:311-320. [PMID: 22828983 DOI: 10.1177/1545109712453939] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
513 Lim LG, Aung MO, Seet BL, Tan C, Dan YY, Lee YM, Sutedja DS, Fernandes M, Lee GH, Koay E, Lim SG. Alanine aminotransferase is an inadequate surrogate marker for detecting lamivudine resistance. World J Gastroenterol 2010; 16(37): 4691-4696 [PMID: 20872970 DOI: 10.3748/wjg.v16.i37.4691] [Reference Citation Analysis]
514 Park H, Lee JM, Seo JH, Kim HS, Ahn SH, Kim DY, Han K, Chon CY, Park JY. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers. Liver Int 2012;32:796-802. [DOI: 10.1111/j.1478-3231.2011.02693.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
515 Reijnders JG, Janssen HL. Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: Is the glass half full or half empty?: Reijnders and Janssen. Hepatology 2013;58:1885-7. [DOI: 10.1002/hep.26708] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
516 Tsai MC, Chen CH, Hung CH, Lee CM, Chiu KW, Wang JH, Lu SN, Tseng PL, Chang KC, Yen YH. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. Clin Microbiol Infect. 2014;20:O90-O100. [PMID: 23659493 DOI: 10.1111/1469-0691.12220] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
517 Wang HL, Lu X, Yang X, Xu N. Antiviral Therapy in Lamivudine-Resistant Chronic Hepatitis B Patients: A Systematic Review and Network Meta-Analysis. Gastroenterol Res Pract 2016;2016:3435965. [PMID: 27672391 DOI: 10.1155/2016/3435965] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
518 Gui HL, Wang H, Yang YH, Wu YW, Zhou HJ, Guo SM, Lin LY, Wang L, Cai W, Chen R, Guo Q, Zhou XQ, Bao SS, Xie Q. Significant histopathology in Chinese chronic hepatitis B patients with persistently high-normal alanine aminotransferase. J Viral Hepat 2010;17 Suppl 1:44-50. [PMID: 20586933 DOI: 10.1111/j.1365-2893.2010.01270.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
519 Chen YC, Huang SF, Chu CM, Liaw YF. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion. J Viral Hepat. 2012;19:138-146. [PMID: 22239503 DOI: 10.1111/j.1365-2893.2011.01450.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
520 Enomoto H, Aizawa N, Nakamura H, Sakai Y, Iwata Y, Tanaka H, Ikeda N, Aoki T, Yuri Y, Yoh K. An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients. Gastroenterol Res Pract. 2014;2014:351396. [PMID: 24693282 DOI: 10.1155/2014/351396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
521 Shan F, Gao C, Long Y, Huang L, Zheng Y, Chen M, Fan Y, Yin J. Cerebral venous sinus thrombosis may be associated with hepatitis B virus infection: a preliminary finding. Neurol Res 2015;37:510-3. [PMID: 25591420 DOI: 10.1179/1743132815Y.0000000003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
522 Ni YH. Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol. 2011;46:1-8. [PMID: 20812021 DOI: 10.1007/s00535-010-0304-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
523 Kim YJ, Paik SW, Sinn DH, Gwak G, Choi MS, Lee JH, Koh KC, Yoo BC. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance: Adefovir add-on in lamivudine-resistance. Journal of Gastroenterology and Hepatology 2012;27:1454-60. [DOI: 10.1111/j.1440-1746.2011.07050.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
524 Saadah OI, Sindi HH, Bin-Talib Y, Al-Harthi S, Al-Mughales J. Entecavir treatment of children 2-16 years of age with chronic hepatitis B infection. Arab J Gastroenterol 2012;13:41-4. [PMID: 22980589 DOI: 10.1016/j.ajg.2012.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
525 Enomoto M, Mori M, Ogawa T, Fujii H, Kobayashi S, Iwai S, Morikawa H, Tamori A, Sakaguchi H, Sawada A. Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. Hepatol Res. 2010;40:853-861. [PMID: 20887589 DOI: 10.1111/j.1872-034x.2010.00687.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 17] [Article Influence: 4.1] [Reference Citation Analysis]
526 Buti M, Tabernero D, Mas A, Homs M, Prieto M, Rodríguez-Frías F, Casafont F, Casillas R, González A, Miras M, Herrero JI, Castells L, Esteban R. Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin. Transpl Infect Dis 2015;17:208-20. [PMID: 25641570 DOI: 10.1111/tid.12360] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
527 Sanai FM, Alghamdi H, Alswat KA, Babatin MA, Ismail MH, Alhamoudi WK, Alalwan AM, Dahlan Y, Alghamdi AS, Alfaleh FZ, Aljumah AA, Altraif IH, Albeladi K, Batwa F, Alshumrani W, Belhadi D, Genestier V, Abdo AA. Greater prevalence of comorbidities with increasing age: Cross-sectional analysis of chronic hepatitis B patients in Saudi Arabia. Saudi J Gastroenterol 2019;25:194-200. [PMID: 30720002 DOI: 10.4103/sjg.SJG_447_18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
528 Kao JT, Lai HC, Tsai SM, Lin PC, Chuang PH, Yu CJ, Cheng KS, Su WP, Hsu PN, Peng CY, Wu YY. Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients. Liver Int 2012;32:928-36. [PMID: 22230324 DOI: 10.1111/j.1478-3231.2011.02742.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
529 Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, Chutaputti A, Rasenack J, Hou J, O’Brien C. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009;51:11-20. [PMID: 19345439 DOI: 10.1016/j.jhep.2008.12.019] [Cited by in Crossref: 154] [Cited by in F6Publishing: 154] [Article Influence: 11.8] [Reference Citation Analysis]
530 Hadziyannis E, Laras A. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes (Basel) 2018;9:E469. [PMID: 30262738 DOI: 10.3390/genes9100469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
531 Enomoto M, Nishiguchi S, Tamori A, Kobayashi S, Sakaguchi H, Shiomi S, Kim SR, Enomoto H, Saito M, Imanishi H. Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol. 2013;48:397-404. [PMID: 22850869 DOI: 10.1007/s00535-012-0645-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
532 Cho HJ, Kim SS, Shin SJ, Yoo BM, Cho SW, Cheong JY. Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance. J Med Virol. 2015;87:1532-1538. [PMID: 25940352 DOI: 10.1002/jmv.24201] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
533 Min L, Chen X, Ye Y, Zhang Q, Ru S, Li X. Modeling and simulating dynamics of complete- and poor-response chronic hepatitis B chinese patients for adefovir and traditional chinese medicine plus adefovir therapy. Evid Based Complement Alternat Med 2013;2013:767290. [PMID: 24282437 DOI: 10.1155/2013/767290] [Cited by in Crossref: 6] [Article Influence: 0.7] [Reference Citation Analysis]
534 Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886-893. [PMID: 20683932 DOI: 10.1002/hep.23785] [Cited by in Crossref: 627] [Cited by in F6Publishing: 596] [Article Influence: 52.3] [Reference Citation Analysis]
535 Kim YJ, Sinn DH, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures. World J Gastroenterol 2012; 18(47): 6996-7002 [PMID: 23322999 DOI: 10.3748/wjg.v18.i47.6996] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
536 Chaung KT, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Garcia G, Ahmed A, Keeffe EB, Nguyen MH. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012;46:865-70. [PMID: 22941429 DOI: 10.1097/MCG.0b013e31825ceed9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
537 Qiu YW, Huang LH, Jiang XH, Hu TH, Ding H, Jiang YM, Dai YX, Zhou M. Treatment of chronic hepatitis B patients harboring YMDD variants. Shijie Huaren Xiaohua Zazhi 2009; 17(29): 3034-3037 [DOI: 10.11569/wcjd.v17.i29.3034] [Reference Citation Analysis]
538 Lai MW, Chang MH. Updates in the management of hepatitis B in children. Expert Rev Gastroenterol Hepatol 2019;13:1065-76. [PMID: 31663387 DOI: 10.1080/17474124.2019.1686975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
539 Sun KX, Li J, Zhu FC, Liu JX, Li RC, Zhai XJ, Li YP, Chang ZJ, Nie JJ, Zhuang H. A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women. Vaccine. 2012;30:5335-5340. [PMID: 22749833 DOI: 10.1016/j.vaccine.2012.06.036] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
540 Khamduang W, Gaudy-Graffin C, Ngo-Giang-Huong N, Jourdain G, Moreau A, Luekamlung N, Halue G, Buranawanitchakorn Y, Kunkongkapan S, Buranabanjasatean S, Lallemant M, Sirirungsi W, Goudeau A; Program for HIV Prevention and Treatment Study Group. Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand. PLoS One 2012;7:e42184. [PMID: 22860080 DOI: 10.1371/journal.pone.0042184] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
541 Li J, Huang B, Li Y, Zheng D, Zhou Z, Liu J. Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant. Leuk Lymphoma. 2015;56:1710-1717. [PMID: 25098429 DOI: 10.3109/10428194.2014.941833] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
542 Tseng T, Liu C, Su T, Yang H, Wang C, Chen C, Kuo SF, Liu C, Chen P, Chen D, Kao J. Young Chronic Hepatitis B Patients With Nucleos(t)ide Analogue-induced Hepatitis B e Antigen Seroconversion Have a Higher Risk of HBV Reactivation. Journal of Infectious Diseases 2012;206:1521-31. [DOI: 10.1093/infdis/jis569] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
543 Liu Y, Zhang S, Zhao Y, Du J, Jin G, Shao S, Lu X. Development and Application of the Chinese (Mainland) Version of Chronic Liver Disease Questionnaire to Assess the Health-Related Quality of Life (HRQoL) in Patients with Chronic Hepatitis B. PLoS One 2016;11:e0162763. [PMID: 27631983 DOI: 10.1371/journal.pone.0162763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
544 Chen J, Zhang DH, Xu CR, Zhu MY, Yang ZT, Gong QM, Yu DM, Zhang XX. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B. J Clin Virol 2015;72:88-94. [PMID: 26476325 DOI: 10.1016/j.jcv.2015.09.012] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
545 Rowe IA, Parker R, Armstrong MJ, King AL, Houlihan DD, Mutimer D. Assessment of the Quality of Evidence Underlying International Guidelines in Liver Disease. American Journal of Gastroenterology 2012;107:1276-82. [DOI: 10.1038/ajg.2012.71] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
546 Nakazawa T, Shibuya A, Takeuchi A, Shibata Y, Hidaka H, Okuwaki Y, Takada J, Tanaka Y, Watanabe M, Minamino T. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels. J Viral Hepat. 2011;18:e191-e199. [PMID: 21692932 DOI: 10.1111/j.1365-2893.2010.01427.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
547 Yang YJ, Shim JH, Kim KM, Lim YS, Lee HC. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology. 2014;59:1303-1310. [PMID: 24170683 DOI: 10.1002/hep.26910] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
548 Croagh CM, Lubel JS. Natural history of chronic hepatitis B: Phases in a complex relationship. World J Gastroenterol 2014; 20(30): 10395-10404 [PMID: 25132755 DOI: 10.3748/wjg.v20.i30.10395] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
549 Leung N. Chronic hepatitis B in Asian women of childbearing age. Hepatol Int. 2009;3 Suppl 1:24-31. [PMID: 19669243 DOI: 10.1007/s12072-009-9142-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
550 Shang J, Wen Q, Wang CC, Liu K, Bai L, Tang H. Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up. J Viral Hepat 2017;24 Suppl 1:43-8. [PMID: 29082646 DOI: 10.1111/jvh.12785] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
551 Li M, Sun XH, Zhou ZH, Yu Z, Jin SG, Zhu XJ, Gao YQ. Beneficial therapeutic effect of Chinese herbal Bushen formula on CHB patients with mildly elevated alanine aminotransferase by down-regulating CD4+CD25+T cells. J Ethnopharmacol. 2013;146:614-622. [PMID: 23395622 DOI: 10.1016/j.jep.2013.01.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
552 Yousaf AM, Jee J, Hwang SR, Maeng H, Park Y, Kim JO, Yong CS, Choi H, Cho KH. Development of direct compression entecavir 0.5 mg-loaded tablet exhibiting enhanced content uniformity. Powder Technology 2014;267:302-8. [DOI: 10.1016/j.powtec.2014.07.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
553 Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Ormeci N, Zondervan PE. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am J Gastroenterol. 2010;105:1762-1769. [PMID: 20461068 DOI: 10.1038/ajg.2010.186] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 5.4] [Reference Citation Analysis]
554 Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 2017; 9(5): 227-241 [PMID: 28261380 DOI: 10.4254/wjh.v9.i5.227] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
555 Jiang L, Hu S, He M, Tian D. Estimated Glomerular Filtration Rate Increases in Chronic Hepatitis B Patients Treated With Telbivudine Monotherapy and Combination Treatment. Hepat Mon 2016;16:e32528. [PMID: 27110258 DOI: 10.5812/hepatmon.32528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
556 Hwang JP, Fisch MJ, Lok AS, Zhang H, Vierling JM, Suarez-Almazor ME. Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center. BMC Cancer 2013;13:534. [PMID: 24209764 DOI: 10.1186/1471-2407-13-534] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
557 Roche B, Samuel D. Universal hepatitis B virus screening in patients receiving immunosuppressive therapy: a small step for the oncologists, a major advance for prevention of hepatitis B virus reactivation. Clin Gastroenterol Hepatol 2015;13:976-8. [PMID: 25632804 DOI: 10.1016/j.cgh.2015.01.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
558 Chong CH, Lim SG. When can we stop nucleoside analogues in patients with chronic hepatitis B? Liver Int. 2017;37 Suppl 1:52-58. [PMID: 28052620 DOI: 10.1111/liv.13314] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
559 Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011;34:1145-1158. [PMID: 21978243 DOI: 10.1111/j.1365-2036.2011.04869.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
560 Chen CH, Lee CM, Hung CH, Wang JH, Hu TH, Changchien CS, Lu SN. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients. J Gastroenterol Hepatol. 2011;26:461-468. [PMID: 21332543 DOI: 10.1111/j.1440-1746.2010.06429.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
561 Wong CR, Trinh HN, Yip B, Nguyen HA, Garcia RT, Ahmed A, Keeffe EB, Nguyen MH. High Rate of Complete Viral Suppression With Combination Therapy in Patients With Chronic Hepatitis B and Prior Treatment Failure. Journal of Clinical Gastroenterology 2011;45:900-5. [DOI: 10.1097/mcg.0b013e318224d64f] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
562 Park H, Park JY, Kim SU, Kim DY, Han KH, Chon CY, Ahn SH. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir. World J Gastroenterol 2013; 19(43): 7671-7679 [PMID: 24431895 DOI: 10.3748/wjg.v19.i43.7671] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
563 Sun L, Shan J, Cui R, Yuan W, Jiang G. Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases. Int Urol Nephrol 2017;49:1049-56. [DOI: 10.1007/s11255-017-1563-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
564 Lai JC, Wong VW, Yip TC, Hui VW, Tse YK, Lee HW, Liang LY, Lui GC, Chan HL, Wong GL. Secular trend of treatment uptake in patients with chronic hepatitis B: A territory-wide study of 135 395 patients from 2000 to 2017. J Gastroenterol Hepatol 2021;36:3487-99. [PMID: 34404113 DOI: 10.1111/jgh.15664] [Reference Citation Analysis]
565 Fung J, Lai C, Yuen M. To stop or not to stop: The quest for long-term viral suppression: Editorials. Journal of Gastroenterology and Hepatology 2011;26:420-2. [DOI: 10.1111/j.1440-1746.2011.06604.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
566 Manzoor S, Saalim M, Imran M, Resham S, Ashraf J. Hepatitis B virus therapy: What’s the future holding for us? World J Gastroenterol 2015; 21(44): 12558-12575 [PMID: 26640332 DOI: 10.3748/wjg.v21.i44.12558] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
567 Gane EJ. The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int. 2008;2:304-307. [PMID: 19669258 DOI: 10.1007/s12072-008-9083-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
568 Yang SC, Lu SN, Lee CM, Hu TH, Wang JH, Hung CH, Changchien CS, Chen CH. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion. Hepatol Int. 2013;7:489-499. [PMID: 26201781 DOI: 10.1007/s12072-012-9382-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
569 Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy. J Viral Hepat 2014;21:288-96. [PMID: 24597697 DOI: 10.1111/jvh.12142] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
570 Orlando R, Foggia M, Maraolo AE, Mascolo S, Palmiero G, Tambaro O, Tosone G. Prevention of hepatitis B virus infection: from the past to the future. Eur J Clin Microbiol Infect Dis. 2015;34:1059-1070. [PMID: 25678010 DOI: 10.1007/s10096-015-2341-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
571 Chung JW, Kim BH, Lee CS, Kim GH, Sohn HR, Min BY, Song JC, Park HK, Jang ES, Yoon H, Kim J, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Lee J, Ahn S, Kim JW. Optimizing Surveillance Performance of Alpha-Fetoprotein by Selection of Proper Target Population in Chronic Hepatitis B. PLoS One 2016;11:e0168189. [PMID: 27997559 DOI: 10.1371/journal.pone.0168189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
572 Chien RN, Liaw YF. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 2008;22:1081-92. [PMID: 19187868 DOI: 10.1016/j.bpg.2008.11.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
573 Chang SW, Fann CS, Su WH, Wang YC, Weng CC, Yu CJ, Hsu CL, Hsieh AR, Chien RN, Chu CM. A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese. PLoS One. 2014;9:e99724. [PMID: 24940741 DOI: 10.1371/journal.pone.0099724] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
574 Liu F, Liu ZR, Li T, Liu Y, Zhang M, Xue Y, Zhang LX, Ye Q, Fan XP, Wang L. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. J Dig Dis. 2018;19:561-571. [PMID: 30098114 DOI: 10.1111/1751-2980.12654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
575 Hara T, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H. Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients. J Viral Hepat 2014;21:802-8. [PMID: 25274427 DOI: 10.1111/jvh.12211] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
576 Hann HW, Gregory VL, Dixon JS, Barker KF. A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B : Lamivudine resistance. Hepatol Int 2008;2:440-56. [PMID: 19669319 DOI: 10.1007/s12072-008-9105-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
577 Ke W, Liu L, Zhang C, Ye X, Gao Y, Zhou S, Yang Y. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS One. 2014;9:e98865. [PMID: 24905092 DOI: 10.1371/journal.pone.0098865] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]
578 Yu C, Gong X, Yang Q, Lian J, Xu K, Ruan B, Li L. The serum IL-23 Level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B. Liver Int. 2015;35:1549-1556. [PMID: 25312687 DOI: 10.1111/liv.12701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
579 Seto WK, Lai CL, Ip PP, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B. PLoS One. 2012;7:e32622. [PMID: 22389715 DOI: 10.1371/journal.pone.0032622] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 4.8] [Reference Citation Analysis]
580 Cheng SH, Mai L, Zhu FQ, Pan XF, Sun HX, Cao H, Shu X, Ke WM, Li G, Xu QH. Influence of chronic HBV infection on superimposed acute hepatitis E. World J Gastroenterol 2013; 19(35): 5904-5909 [PMID: 24124337 DOI: 10.3748/wjg.v19.i35.5904] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
581 Huang Y, Deng H, Shan X, Gong X, Li X, Tu Z, Long Q, Huang A. Lower mutation frequency of BCP/precore regions in e antigen-negative chronic HBV-infected children instead of adults patients. PLoS One. 2015;10:e0120733. [PMID: 25822176 DOI: 10.1371/journal.pone.0120733] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
582 Md Yusof MY, Vital EM, Buch MH. B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. Curr Rheumatol Rep 2015;17:65. [PMID: 26290110 DOI: 10.1007/s11926-015-0539-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
583 Chen J, Yi L, Jia JD, Ma H, You H. Hepatitis B immunoglobulins and/or lamivudine for preventing hepatitis B recurrence after liver transplantation: a systematic review. J Gastroenterol Hepatol. 2010;25:872-879. [PMID: 20546440 DOI: 10.1111/j.1440-1746.2009.06151.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
584 Lin S, Sun Q, Mao W, Chen Y. Serum Immunoglobulin A (IgA) Level Is a Potential Biomarker Indicating Cirrhosis during Chronic Hepatitis B Infection. Gastroenterol Res Pract 2016;2016:2495073. [PMID: 27123003 DOI: 10.1155/2016/2495073] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
585 Viganò M, Invernizzi F, Lampertico P. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients? Liver Int 2015;35:107-13. [DOI: 10.1111/liv.12717] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
586 Chen DS, Locarnini S, Wait S, Bae SH, Chen PJ, Fung JY, Kim HS, Lu SN, Sung J, Tanaka J, Wakita T, Ward J, Wallace J; CEVHAP North Asia Workshop on Viral Hepatitis. CEVHAP North Asia Workshop on Viral Hepatitis. Report from a Viral Hepatitis Policy Forum on implementing the WHO Framework for Global Action on viral hepatitis in North Asia. J Hepatol. 2013;59:1073-1080. [PMID: 23850942 DOI: 10.1016/j.jhep.2013.06.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
587 Tseng T, Liu C, Chen C, Wang C, Su T, Kuo SF, Chen P, Chen D, Kao J. Serum Hepatitis B Virus-DNA Levels Correlate With Long-term Adverse Outcomes in Spontaneous Hepatitis B e Antigen Seroconverters. The Journal of Infectious Diseases 2012;205:54-63. [DOI: 10.1093/infdis/jir687] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
588 Chan SL, Wong VW, Qin S, Chan HL. Infection and Cancer: The Case of Hepatitis B. J Clin Oncol. 2016;34:83-90. [PMID: 26578611 DOI: 10.1200/jco.2015.61.5724] [Cited by in Crossref: 81] [Cited by in F6Publishing: 41] [Article Influence: 11.6] [Reference Citation Analysis]
589 Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Wong VW. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013;144:933-944. [PMID: 23415803 DOI: 10.1053/j.gastro.2013.02.002] [Cited by in Crossref: 120] [Cited by in F6Publishing: 120] [Article Influence: 13.3] [Reference Citation Analysis]
590 Wang X, Jiang W, Li F, Hua F, Zhan Y, Li Y, Ji L, Zou S, Min Z, Song D, Cheng Y. Abnormal platelet kinetics are detected before the occurrence of thrombocytopaenia in HBV-related liver disease. Liver Int 2014;34:535-43. [DOI: 10.1111/liv.12309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
591 Wang W, Liang H, Zeng Y, Lin J, Liu C, Jiang L, Yang B, Ou Q. Establishment of a novel two-probe real-time PCR for simultaneously quantification of hepatitis B virus DNA and distinguishing genotype B from non-B genotypes. Clinica Chimica Acta 2014;437:168-74. [DOI: 10.1016/j.cca.2014.07.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
592 Tai DI, Tsay PK, Chen WT, Chu CM, Liaw YF. Relative roles of HBsAg seroclearance and mortality in the decline of HBsAg prevalence with increasing age. Am J Gastroenterol. 2010;105:1102-1109. [PMID: 20197760 DOI: 10.1038/ajg.2009.669] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
593 Tseng T, Liu C, Su T, Wang C, Chen C, Chen P, Chen D, Kao J. Serum Hepatitis B Surface Antigen Levels Predict Surface Antigen Loss in Hepatitis B e Antigen Seroconverters. Gastroenterology 2011;141:517-525.e2. [DOI: 10.1053/j.gastro.2011.04.046] [Cited by in Crossref: 138] [Cited by in F6Publishing: 142] [Article Influence: 12.5] [Reference Citation Analysis]
594 Oh MJ, Lee HJ. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience. Clin Mol Hepatol. 2013;19:51-59. [PMID: 23593610 DOI: 10.3350/cmh.2013.19.1.51] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
595 Pipili C, Cholongitas E. Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation. World J Hepatol 2014; 6(5): 315-325 [PMID: 24868325 DOI: 10.4254/wjh.v6.i5.315] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
596 Lim JK, Ayoub WS, Nguyen MH. Histologic Disease in Patients with Chronic Hepatitis B, High HBV DNA, and Normal Alanine Aminotransferase Levels. Curr Hepatitis Rep 2010;9:65-74. [DOI: 10.1007/s11901-010-0040-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
597 Ridruejo E. Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma? Expert Opin Drug Saf 2015;14:439-51. [PMID: 25547687 DOI: 10.1517/14740338.2015.998649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
598 Dai CY, Tseng TC, Wong GL, Huang JF, Wong VW, Liu CJ, Yu ML, Chuang WL, Kao JH, Chan HL, Chen DS. Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. J Antimicrob Chemother. 2013;68:2332-2338. [PMID: 23798667 DOI: 10.1093/jac/dkt193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
599 Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, Yasuda S, Andou Y, Yamamoto K, Tanaka J. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2013;58:427-433. [PMID: 23123221 DOI: 10.1016/j.jhep.2012.10.025] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 9.5] [Reference Citation Analysis]
600 Nie R, Wang M, Liao T, Qian K, Zhu G, Jin L. Assisted conception does not increase the risk for mother-to-child transmission of hepatitis B virus, compared with natural conception: a prospective cohort study. Fertil Steril 2019;111:348-56. [PMID: 30691633 DOI: 10.1016/j.fertnstert.2018.10.021] [Reference Citation Analysis]
601 Pan AN, Xu WW, Luo YL, Yu HH, Hu YB, Sun QF, Ding JG, Wu YH. A novel system for predicting liver histopathology in patients with chronic hepatitis B. Medicine (Baltimore) 2017;96:e6465. [PMID: 28383410 DOI: 10.1097/MD.0000000000006465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
602 Xu H, Zeng T, Liu JY, Lei Y, Zhong S, Sheng YJ, Zhou Z, Ren H. Measures to reduce mother-to-child transmission of Hepatitis B virus in China: a meta-analysis. Dig Dis Sci 2014;59:242-58. [PMID: 24193353 DOI: 10.1007/s10620-013-2918-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
603 Fung J, Lai CL, Seto WK, Yuen MF. The use of transient elastography in the management of chronic hepatitis B. Hepatol Int. 2011;5:868-875. [PMID: 21695588 DOI: 10.1007/s12072-011-9288-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
604 Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J. Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? Bull World Health Organ 2010;88:66-73. [PMID: 20428355 DOI: 10.2471/BLT.08.065722] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
605 Vassilopoulos D. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Intern Med. 2011;22:572-575. [PMID: 22075282 DOI: 10.1016/j.ejim.2011.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
606 Fang Q, Hao YH, Li L, Zhang ZH, Wang JZ, Chen MF, Kang J, Yang DL. Chronic HBV carrier's acceptance of regular surveilling program in China. J Huazhong Univ Sci Technolog Med Sci 2013;33:288-92. [PMID: 23592146 DOI: 10.1007/s11596-013-1113-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
607 Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021; 13(9): 1042-1057 [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Reference Citation Analysis]
608 Zeng LY, Lian JS, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, Li LJ, Yang YD. Hepatitis B surface antigen levels during natural history of chronic hepatitis B: A Chinese perspective study. World J Gastroenterol 2014; 20(27): 9178-9184 [PMID: 25083092 DOI: 10.3748/wjg.v20.i27.9178] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
609 Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol Res 2020;50:892-923. [PMID: 32343469 DOI: 10.1111/hepr.13504] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
610 Sali S, Merza MA, Saadat S, Mustafa NH, Queiky F, Yadegarynia D. Seroclearance of Hbsag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year Experience. Glob J Health Sci 2015;7:101-7. [PMID: 26153167 DOI: 10.5539/gjhs.v7n6p101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
611 Marignani M, Canzoni M, D'Amelio R, De Santis E, Pecchioli A, Delle Fave G. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO. Eur J Intern Med 2011;22:576-81. [PMID: 22075283 DOI: 10.1016/j.ejim.2011.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
612 Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection. Cochrane Database Syst Rev 2013;:CD009004. [PMID: 23633363 DOI: 10.1002/14651858.CD009004.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
613 Park CH, Kim HY, Lee SW, Song do S, Song MJ, Kwon JH, You CR, Jang JW, Kim CW, Choi SW, Bae SH, Choi JY, Yoon SK. On-treatment and off-treatment efficacy of entecavir in a real-life cohort of chronic hepatitis B patients. Eur J Gastroenterol Hepatol 2016;28:1179-87. [PMID: 27428552 DOI: 10.1097/MEG.0000000000000691] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
614 Hsiang JC, Wong GL, Chan HL, Chan AW, Chim AM, Wong VW. Metabolic syndrome delays HBeAg seroclearance in Chinese patients with hepatitis B. Aliment Pharmacol Ther. 2014;40:716-726. [PMID: 25039861 DOI: 10.1111/apt.12874] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
615 Lee HW, Kang W, Ahn SH, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Kim JK, Kim DY, Paik YH, Lee CK, Choi IS, Lee KS, Han KH. Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients. J Gastroenterol Hepatol 2014;29:1049-55. [PMID: 24575848 DOI: 10.1111/jgh.12522] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
616 Wong GL, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Wong VW. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339-345. [PMID: 24128413 DOI: 10.1016/j.jhep.2013.09.029] [Cited by in Crossref: 155] [Cited by in F6Publishing: 130] [Article Influence: 17.2] [Reference Citation Analysis]
617 Piratvisuth T, Marcellin P, Popescu M, Kapprell H, Rothe V, Lu Z. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2013;7:429-36. [DOI: 10.1007/s12072-011-9280-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 6.5] [Reference Citation Analysis]
618 Huang YJ, Chang CS, Peng YC, Yeh HZ, Yang SS. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B. PLoS One 2017;12:e0174046. [PMID: 28350873 DOI: 10.1371/journal.pone.0174046] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
619 Hadziyannis SJ, Vassilopoulos D, Sevastianos V, Hadziyannis E. Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B? Curr Hepatology Rep 2014;13:256-63. [DOI: 10.1007/s11901-014-0236-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
620 Lee YB, Jung EU, Kim BH, Lee JH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. Antimicrob Agents Chemother. 2015;59:972-978. [PMID: 25421484 DOI: 10.1128/AAC.04454-14] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
621 Lim YS, Lee JY, Lee D, Shim JH, Lee HC, Lee YS, Suh DJ. Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir. Antimicrob Agents Chemother. 2012;56:2941-2947. [PMID: 22430972 DOI: 10.1128/aac.00338-12] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
622 Viganò M, Serra G, Casella G, Grossi G, Lampertico P. Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders. Expert Opin Biol Ther 2016;16:917-26. [PMID: 27088278 DOI: 10.1080/14712598.2016.1177017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
623 Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2015;42:243-257. [PMID: 26151841 DOI: 10.1111/apt.13272] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 11.0] [Reference Citation Analysis]
624 Zhen J, Zhang L, Pan J, Ma S, Yu X, Li X, Chen S, Du W. AIM2 mediates inflammation-associated renal damage in hepatitis B virus-associated glomerulonephritis by regulating caspase-1, IL-1β, and IL-18. Mediators Inflamm 2014;2014:190860. [PMID: 24701032 DOI: 10.1155/2014/190860] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
625 Block TM, Rawat S, Brosgart CL. Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res. 2015;121:69-81. [PMID: 26112647 DOI: 10.1016/j.antiviral.2015.06.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
626 Paul N, Han SH. Combination Therapy for Chronic Hepatitis B: Current Indications. Curr Hepat Rep 2011;10:98-105. [PMID: 21654909 DOI: 10.1007/s11901-011-0095-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
627 Chaung KT, O'Brien C, Ha NB, Nguyen NH, Trinh HN, Nguyen MH. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy. J Clin Gastroenterol. 2016;50:338-344. [PMID: 26646801 DOI: 10.1097/MCG.0000000000000455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
628 Zeng DW, Liu YR, Zhang JM, Zhu YY, Lin S, You J, Li YB, Chen J, Zheng Q, Jiang JJ, Dong J. Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease. PLoS One. 2013;8:e77942. [PMID: 24282481 DOI: 10.1371/journal.pone.0077942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
629 Shin JG, Cheong HS, Kim JY, Lee JH, Yu SJ, Yoon JH, Cheong JY, Cho SW, Park NH, Namgoong S, Kim LH, Kim YJ, Shin HD. Identification of additional EHMT2 variant associated with the risk of chronic hepatitis B by GWAS follow-up study. Genes Immun 2019;20:1-9. [PMID: 29238036 DOI: 10.1038/s41435-017-0004-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
630 Wu B, Shen J, Cheng H. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China. BMC Health Serv Res. 2012;12:385. [PMID: 23137013 DOI: 10.1186/1472-6963-12-385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
631 Uribe LA, O’brien CG, Wong RJ, Gish RR, Tsai N, Nguyen MH. Current Treatment Guidelines for Chronic Hepatitis B and Their Applications. Journal of Clinical Gastroenterology 2014;48:773-83. [DOI: 10.1097/mcg.0000000000000130] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
632 Kim MN, Hwang SG, Rim KS, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir. Liver Int 2017;37:1788-95. [PMID: 28418595 DOI: 10.1111/liv.13450] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
633 Wu I, Lai C, Han SB, Han K, Gordon SC, Chao Y, Tan C, Sievert W, Tanwandee T, Xu D, Neo B, Chang T. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010;51:1185-9. [DOI: 10.1002/hep.23424] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]
634 Yu LH, Li N, Shi J, Guo WX, Wu MC, Cheng SQ. Does anti-HBV therapy benefit the prognosis of HBV-related hepatocellular carcinoma following hepatectomy? Ann Surg Oncol. 2014;21:1010-1015. [PMID: 24121884 DOI: 10.1245/s10434-013-3320-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
635 Choi HN, Song JE, Lee HC, Jo HH, Lee CH, Kim BS. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir. Clin Mol Hepatol 2015;21:24-31. [PMID: 25834799 DOI: 10.3350/cmh.2015.21.1.24] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
636 Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
637 Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Res Ther 2019;21:255. [PMID: 31779676 DOI: 10.1186/s13075-019-2053-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
638 Cengiz M, Ozenirler S. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:1293-1299. [PMID: 26302023 DOI: 10.1097/meg.0000000000000445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
639 Wu B, Li T, Chen H, Shen J. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health. 2010;13:592-600. [PMID: 20561341 DOI: 10.1111/j.1524-4733.2010.00733.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
640 Orito E, Hasebe C, Kurosaki M, Osaki Y, Joko K, Watanabe H, Kimura H, Nishijima N, Kusakabe A, Izumi N; Japanese Red Cross Liver Network. Risk of hepatocellular carcinoma in cirrhotic hepatitis B virus patients during nucleoside/nucleotide analog therapy. Hepatol Res 2015;45:872-9. [PMID: 25244601 DOI: 10.1111/hepr.12427] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
641 Sun S, Dai J, Fang J, Gou X, Cao H, Zheng N, Wang Y, Zhang W, Zhang Y, Jia W, Hu Y. Differences of excess and deficiency zheng in patients with chronic hepatitis B by urinary metabonomics. Evid Based Complement Alternat Med 2013;2013:738245. [PMID: 23710235 DOI: 10.1155/2013/738245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
642 Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol. 2011;106:1766-1773. [PMID: 21826112 DOI: 10.1038/ajg.2011.253] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
643 Lok AS. Drug therapy: tenofovir. Hepatology. 2010;52:743-747. [PMID: 20597070 DOI: 10.1002/hep.23788] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
644 Singal AK, Fontana RJ. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther. 2012;35:674-689. [PMID: 22257108 DOI: 10.1111/j.1365-2036.2011.04990.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
645 Peveling-Oberhag J, Herrmann E, Kronenberger B, Farnik H, Susser S, Sarrazin C, Zeuzem S, Hofmann WP. Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs. J Viral Hepat. 2013;20:234-239. [PMID: 23490367 DOI: 10.1111/jvh.12013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
646 Woo HY, Park JY, Bae SH, Kim CW, Jang JY, Tak WY, Kim DJ, Kim IH, Heo J, Ahn SH. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response. Clin Mol Hepatol 2020;26:352-63. [PMID: 32460460 DOI: 10.3350/cmh.2019.0044n] [Reference Citation Analysis]
647 Turker K, Oksuzoglu B, Balci E, Uyeturk U, Hascuhadar M. Awareness of hepatitis B virus reactivation among physicians authorized to prescribe chemotherapy. Eur J Intern Med 2013;24:e90-2. [PMID: 23953849 DOI: 10.1016/j.ejim.2013.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
648 Yu SJ, Lee JH, Chung GE, Lee CH, Cho EJ, Jang ES, Kwak MS, Kim YJ, Yoon JH, Jang JJ, Lee HS. Validation of P2/MS for reflecting hepatic fibrosis in patients with hepatocellular carcinoma. Korean J Hepatol 2010;16:389-96. [PMID: 21415583 DOI: 10.3350/kjhep.2010.16.4.389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
649 Wang Y, Wang W, Shen C, Wang Y, Jiao M, Yu W, Yin H, Shang X, Liang Q, Zhao C. NKG2D modulates aggravation of liver inflammation by activating NK cells in HBV infection. Sci Rep 2017;7:88. [PMID: 28273905 DOI: 10.1038/s41598-017-00221-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
650 Yue-Meng W, Yang LH, Yang JH, Xu Y, Yang J, Song GB. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. Hepatol Int. 2016;10:462-469. [PMID: 26482576 DOI: 10.1007/s12072-015-9667-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
651 Cui G, Xu X, Diao H. Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B. Sci Rep 2015;5:11854. [PMID: 26165204 DOI: 10.1038/srep11854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
652 Kim LH, Chaung KT, Ha NB, Kin KC, Vu VD, Trinh HN, Nguyen HA, Nguyen MH. Tenofovir monotherapy after achieving complete viral suppression on entecavir plus tenofovir combination therapy. Eur J Gastroenterol Hepatol. 2015;27:871-876. [PMID: 25919771 DOI: 10.1097/meg.0000000000000368] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
653 Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B vaccines. Vaccines. Elsevier; 2013. pp. 205-34. [DOI: 10.1016/b978-1-4557-0090-5.00025-2] [Cited by in Crossref: 14] [Article Influence: 1.6] [Reference Citation Analysis]
654 Akbar SM, Al-Mahtab M, Hiasa Y. Future aspects of therapy for hepatitis B virus infection: value of surrogate markers, innovative therapy, and global collaboration. J Gastroenterol 2011;46:717-23. [PMID: 21526371 DOI: 10.1007/s00535-011-0401-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
655 Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM, Lok AS. Present and future therapies of hepatitis B: From discovery to cure. Hepatology. 2015;62:1893-1908. [PMID: 26239691 DOI: 10.1002/hep.28025] [Cited by in Crossref: 193] [Cited by in F6Publishing: 182] [Article Influence: 27.6] [Reference Citation Analysis]
656 Chan WK, Tan S, Mohamed R. Stopping Therapy in HBeAg Negative Disease. Curr Hepatitis Rep 2013;12:105-11. [DOI: 10.1007/s11901-013-0167-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
657 Santantonio TA, Fasano M. Chronic hepatitis B: Advances in treatment. World J Hepatol 2014; 6(5): 284-292 [PMID: 24868322 DOI: 10.4254/wjh.v6.i5.284] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
658 Jutavijittum P, Andernach IE, Yousukh A, Samountry B, Samountry K, Thammavong T, Keokhamphue J, Toriyama K, Muller CP. Occult hepatitis B infections among blood donors in Lao PDR. Vox Sang 2014;106:31-7. [PMID: 23931585 DOI: 10.1111/vox.12073] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
659 Lee J, Yoon J, Cho EJ, Yang HJ, Jang ES, Kwak M, Hwang SY, Yu SJ, Lee C, Kim YJ, Kim CY, Lee H. Simple Scoring System Predicting Genotypic Resistance During Rescue Therapy for Lamivudine-Resistant Chronic Hepatitis B. Journal of Clinical Gastroenterology 2012;46:243-50. [DOI: 10.1097/mcg.0b013e318225f559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
660 Chan HLY, Ahn SH, Chang TT, Peng CY, Wong D, Coffin CS, Lim SG, Chen PJ, Janssen HLA, Marcellin P, Serfaty L, Zeuzem S, Cohen D, Critelli L, Xu D, Wind-Rotolo M, Cooney E;  LIRA-B Study Team. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). J Hepatol. 2016;64:1011-1019. [PMID: 26739688 DOI: 10.1016/j.jhep.2015.12.018] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
661 Huang L, Li J, Yan J, Sun J, Zhang X, Wu M, Yan Y. Antiviral therapy decreases viral reactivation in patients with hepatitis B virus-related hepatocellular carcinoma undergoing hepatectomy: a randomized controlled trial. J Viral Hepat. 2013;20:336-342. [PMID: 23565616 DOI: 10.1111/jvh.12036] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
662 Ke W, Zhang C, Liu L, Gao Y, Yao Z, Ye X, Zhou S, Yang Y. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China. Hepatol Int 2016;10:924-36. [PMID: 27271357 DOI: 10.1007/s12072-016-9741-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
663 Block TM, Gish R, Guo H, Mehta A, Cuconati A, Thomas London W, Guo JT. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res. 2013;98:27-34. [PMID: 23391846 DOI: 10.1016/j.antiviral.2013.01.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
664 Yin GQ, Zhong B. Efficacy of interferon for chronic hepatitis B in patients with nucleoside and nucleotide combination therapy failure. J Gastroenterol Hepatol. 2016;31:248-255. [PMID: 26456953 DOI: 10.1111/jgh.13191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
665 Yeh ML, Huang CF, Huang CI, Liu SF, Yang HL, Hsieh MY, Huang JF, Dai CY, Chuang WL, Yu ML. Abbott RealTime HBV assay is more sensitive in detection of low viral load and little impacted by drug resistant mutation in chronic hepatitis B patients under nucleot(s)ide analogues therapy. PLoS One 2014;9:e101790. [PMID: 25000502 DOI: 10.1371/journal.pone.0101790] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]